Protocol PROSPECT Confidential 
Version #:  4.0 Version Date: 2016_0909   Page 2 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012 PROTOCOL AGREEMENT 
I have read the protocol specified below. In my formal capacity as Investigator, my duties 
include ensuring the safety of the study subjects enrolled under my supervision and 
providing the Sponsor with complete and timely information, as outlined in the protocol.  It 
is understood that all information pertaining to the study will be held strictly confidential 
and that this confidentiality requirement applies to all study staff at this site. Furthermore, 
on behalf of the study staff and myself, I agree to maintain the procedures required to carry 
out the study in accordance with accepted GCP principles and to abide by the terms of this 
protocol. 
Protocol Number:  PROSPECT- OB-14 
Protocol Title:      A Two-Part Multicenter Prospective Longitudinal Study of C FTR-Dependent 
Disease Profiling In Cystic Fibrosis ( PROSPECT)  
Protocol Date:  09 September 2016 
Investigator Signature Date  
Print Name and Title  
Site #  
Site Name  
Address  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 3 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  TABLE OF CONTENTS  
 
1 BACKGROUND AND RATIO NALE  ................................ ................................ ...............................  7 
1.1 PART A CORE  STUDY RATIONALE  ................................ ................................ ................................ ........  8 
1.2 PART B CORE  STUDY RATIONALE  ................................ ................................ ................................ ..................  9 
2 RISK AND BENEFIT ASS ESMENT  ................................ ................................ ............................... 15 
3 STUDY OBJECTIVES  ................................ ................................ ................................ ..................... 17 
3.1 PRIMARY OBJECTIVE  ................................ ................................ ................................ ............................  17 
3.2 SECONDARY OBJECTIVES  ................................ ................................ ................................ ............................  17 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ...18 
4.1 STUDY OVERVIE W ................................ ................................ ................................ ................................ ..... 18 
5 CRITERIA FOR EVALUAT ION  ................................ ................................ ................................ ....21 
5.1 PART A ................................ ................................ ................................ ................................ .................  21 
5.2 PART B ................................ ................................ ................................ ................................ .................  21 
5.3 SAFETY EVALUATIONS (PART A AND PART B) ................................ ................................ .....................  23 
6 SUBJECT SELECTION  ................................ ................................ ................................ ................... 24 
6.1 STUDY POPULATION  ................................ ................................ ................................ .............................  24 
6.2 PART  A ................................ ................................ ................................ ................................ ...............  24 
6.3 PART  B ................................ ................................ ................................ ................................ ..................  27 
6.4 STUDY  SPECIFIC TOLERANCE FOR INCLUSION /EXCLUSION CRITERIA  ................................ ..................  30 
6.5 SCREEN FAIL CRITERIA  ................................ ................................ ................................ ........................  30 
7 CONCURRENT MEDICATIO NS ................................ ................................ ................................ ...31 
7.1 PART  A................................ ................................ ................................ ................................ ..................  31 
7.2 PART  B ................................ ................................ ................................ ................................ ..................  31 
8 STUDY PROCEDURES AND  GUIDELINES  ................................ ................................ ................. 33 
8.1 CLINICAL ASSESSMENTS  ................................ ................................ ................................ ......................  33 
8.2 CLINICAL LABORATORY MEASUREMENTS  ................................ ................................ ................................ .......  37 
8.3 RESEARC H LABORATORY MEASUREMENTS  ................................ ................................ .........................  37 
8.4 SPECIMENS FOR LONG-TERM BIOREPOSITORY STORAGE  ................................ ................................ ..... 39 
9 EVALUATIONS BY VISIT  ................................ ................................ ................................ ...................... 40 
9.1 PART A CORE  STUDY – NORMAL CONTROLS ONLY ................................ ................................ ...........  40 
9.2 PART A CORE  STUDY – CF SUBJECTS (WITH OR WITHOUT P H PILL) ................................ ...................  42 
9.3 PART B CORE  STUDY ONLY ................................ ................................ ................................ ................  47 
9.4 PART B CORE  STUDY PLUS MBW/FENO  ................................ ................................ ...........................  51 
9.5 PART B CORE  STUDY PLUS MBW /FENO  WITH MCC  ................................ ................................ ........  55 
9.6 PART B CORE  STUDY PLUS GIFT  ................................ ................................ ................................ ........  61 
9.7 PART B CORE  STUDY PLUS GIFT  WITH P H PILL ................................ ................................ .................  68 
10 ADVERSE EXPERIENCE R EPORTING AND DOCUMEN TATION  ................................ .......... 77 
10.1 ADVERSE EVENTS ................................ ................................ ................................ ............................  77 
10.2 SERIOUS ADVERSE EXPERIENCES (SAE)  ................................ ................................ ................................ .... 78 
10.3 PROTOCOL DEFINED IMPORTANT MEDICAL FINDINGS REQUIRING REAL TIME REPORTING  ................................ .. 79 
10.4 MEDICAL MONITO RING ................................ ................................ ................................ ........................  79 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 4 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  11 DISCONTINUATION AND REPLACEMENT OF SUBJE CTS  ................................ .................... 80 
11.1 WITHDRAWAL OF SUBJECTS FROM THE STUDY  ................................ ................................ ...........................  80 
11.2 REPLACEMENT OF SUBJECTS  ................................ ................................ ................................ ...................  80 
12 PROTOCOL VIOLATIONS  ................................ ................................ ................................ ............ 80 
13 STATISTICAL METHODS AND CON SIDERATIONS  ................................ ................................ 81 
13.1 DATA SETS ANALYZED ................................ ................................ ................................ ....................  81 
13.2 DEMOGRAPHIC AND BASELINE CHARACTERISTICS  ................................ ................................ ..........  81 
13.3 ANALYSIS OF PRIMARY ENDPOINTS  ................................ ................................ ................................  81 
13.4 ANALYSIS OF SECONDARY ENDPOINTS  ................................ ................................ ...........................  82 
13.5 INTERIM ANALYSIS  ................................ ................................ ................................ ..........................  83 
13.6 SAMPLE SIZE ................................ ................................ ................................ ................................ ... 83 
14 DATA COLLECTION, RET ENTION AND CLINICAL MONITORING  ................................ ............................ 85 
14.1 DATA COLLECTION INSTRUMENTS  ................................ ................................ ................................ .. 85 
14.2 DATA MANAGEMENT PROCEDURES ................................ ................................ .............................  8685 
14.3 SECURITY AND ARCHIVAL OF DATA ................................ ................................ ................................  86 
14.4 AVAILABILITY AND RETENTION OF INVESTIGATIONAL RECORDS  ................................ ....................  87 
14.5 MONITORING  ................................ ................................ ................................ ................................ ... 87 
14.6 SUBJECT CONFIDENTIALITY  ................................ ................................ ................................ ............  87 
15 ADMINISTRATIVE, ETHI CAL, REGULATORY CONS IDERATIONS  ................................ .....88 
15.1 PROTOCOL AMENDMENTS  ................................ ................................ ................................ ...............  88 
15.2 INSTITUTIONAL REVIEW BOARDS AND INDEPENDENT ETHICS COMMITTEES  ................................ ... 88 
15.3 INFORMED CONSENT FORM  ................................ ................................ ................................ .............  89 
15.4 PUBLICATIONS  ................................ ................................ ................................ ................................ . 89 
15.5 INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ................................ ... 89 
16. REFERENCES:  ................................ ................................ ................................ ................................ ......... 91 
APPENDIX 1:  SCHEDUL E OF EVENTS - PART A (COHORT 1: NO RMAL CONTROLS)  .............. 96 
APPENDIX 2:  SCHEDUL E OF EVENTS - PART A (COHORTS 2 AN D 3)  ................................ .......... 97 
APPENDIX 3: SCHEDULE  OF EVENTS – PART B  ................................ ................................ .............. 99 
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 5 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  LIST OF ABBREVIATION S AND ACRONYMS  
AE adverse event  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
BUN  blood  urea nitrogen  
CBM  Center for Biochemical Markers  
CC cough clearance  
CF Cystic fibrosis  
CFR  Code of Federal Regulations  
CFRD  cystic fibrosis related diabetes  
CFTR  cystic fibrosis transmembrane conductance regulator  
CF cystic fibrosis  
CFF  Cystic Fib rosis Foundation  
CFFT  Cystic Fibrosis Foundation Therapeutics  
CRF  case report form  
CT computerized tomography  
DMC  Data Monitoring Committee  
DSMB  Data Safety Monitoring Board  
EDC  electronic data capture  
FDA  Food and Drug Administration  
FENO  fraction  of exhaled nitric oxide  
FEV 1 forced expiratory volume over one second  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl transferase  
GI gastro -intestinal  
GIFT  Gastro -intestinal  and Insulin Function Testing  
HIPAA Health Insurance Portability and Accountab ility Act of 1996  
ICF informed consent form  
ICH  International Conference on Harmonisation  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IV intravenous  
LCI lung clearance index  
MBW  multiple breath washout  
MCC  mucociliary clearance  
mEq  milliequivalent  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 6 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  mg milligram  
mL milliliter  
MTA  Master Trial Agreement  
NPD  Nasal potential difference  
OGTT  oral glucose tolerance test  
PFT  pulmonary function test  
PI Principal Investigator  
PI pancreatic insufficient (pancreatic insufficiency)  
PS Pancreatic sufficient  
RC Research Coordinator  
REM  Roentgen equivalent in man 
SAE  serious adverse experience  
SGOT  serum glutamic  oxaloacetic transaminase  
SGPT  serum glutamate pyruvate transaminase  
SIBO  small intestinal bacterial overgrowth  
TDN  Therapeutics Development Network  
TDNCC  Therapeutics Development Network Coordinating Center  
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 7 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  1 BACKGROUND  AND RATIONALE  
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding the 
cystic fibrosis transmembrane conductance regulat or (CFTR) protein. Over 1,900 
mutations, categorized into five genotypic or functional classes are implicated in causing 
CF. Severity of disease varies widely in CF based on CFTR -dependent and independent 
factors. Progressive obstructive lung disease is th e main determinant of morbidity and 
mortality in CF; therefore it is critical to identify biomarker profiles that reflect and predict 
this phenotypic variability, and understand their relationship to residual CFTR activity. 
Emerging CFTR modulator therapie s that directly target defective CFTR are being 
evaluated in pivotal clinical trials and may become available in the next few years. It is not 
known how partial restoration of CFTR function might impact CF disease progression and 
disease -related biomarkers . Thus there is urgent need to i) identify and validate biomarkers 
that might reflect partial restoration of CFTR function and can be used to monitor disease 
progression, and ii) evaluate the mechanistic effects of CFTR modulators on biomarkers and 
explora tory outcome measures in individuals with CF.  
This is a two-part, multi -center, prospective longitudinal, exploratory study of biomarkers, 
clinical and physiological profiles in CF.      
Part A  CORE  Study:  This study is designed to collect specimens and cli nical data to better 
understand the molecular mediators and profiles that characterize specific levels of CFTR 
activity in three different cohorts.  
 Cohort 1: Healthy Controls  
 Cohort 2: CF Subjects with Partial CFTR function CF (class IV/V CFTR mutations)  
 Cohort 3: CF Subjects with Absent CFTR function CF (Class I/II CFTR mutations)  
Part B CORE  Study : The regulatory approval of lumacaftor and ivacaftor combination 
therapy for the treatment of CF  patients 12 years and older  who are homozygous for the 
F508del  mutation  (July 2015) , anticipated expansion of regulatory approval  to include CF 
patients 6 -11 years of age homozygous for the F508del mutation (Fall 2016) and the 
extensive baseline profiling obtained for homozygous F508del Cohort 3 subjects during 
Part A of this study pr ovides an unprecedented opportunity to  evaluate the impact of 
combination CFTR modulator therapy on various biomarkers and other potential outcome 
measures to enable current and future research in this arena.  If the combination therapy is 
approved by  the FDA for use in CF patients  ages 6 to 11 , Part B will be expanded to allow 
for the enrollment of this young er age group . During Part B , additional specimens and 
clinical data will be collected.  Several exploratory outcome measures will a lso be 
evaluated in nested sub -studies . 
Part A and B Cell Culture Bank:  An additional goal of the combined Parts A and B of 
this study is to collect nasal epithelial cells from a sub -set of subjects to develop a cell 
culture bank of sustained primary nasal  epithelium for in vitro analysis of disease 
mechanism and response to experimental therapeutics.  The cell culture bank will be 
established to facilitate use of primary nasal cells by approved investigators with 
appropriate IRB and MTA approvals.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 8 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  1.1 Part A C ORE Study Rationale  
It is not clear how different genotypic classes with distinct CFTR protein abnormalities and 
varying degrees of residual protein function impact the pathophysiology of CF lung disease . 
Each of the CFTR mutations (>1,900 described) resul t in different functional protein 
consequences, ranging from complete protein absence to defective protein activity at the 
plasma membrane. CFTR mutations are broadly categorized into five classes based on the 
molecular effect of the gene mutation on the C FTR protein function.1 Class I (nonsense 
mutations) include premature termination codons and frame shift mutations that result in 
either no significant protein synthesis or low levels of truncated CFTR proteins. Class II 
mutations, which includes the most common F508del mu tant, cause folding or maturation 
defects, and little detectable CFTR at the plasma membrane. Class III mutations ( e.g., 
G551D) lead to the formation of CFTR proteins which reach the plasma membrane but are 
nonfunctional secondary to gating defects that li mit channel opening. As such, Class I -III 
mutations typically have minimal protein function and are associated with a classic CF 
phenotype including pancreatic insufficiency . Class IV and V mutations are associated with 
either reduced chloride conductance through the CFTR protein or reduced levels of the 
CFTR protein at the plasma membrane, respectively. Individuals with one Class IV or V 
mutation typically have residual CFTR function ( i.e., partial function mutations), often have 
sufficient pancreatic func tion to absorb nutrients without supplemental pancreatic enzymes 
(i.e., pancreatic sufficiency ), and may have sweat chloride values in the CF diagnostic or 
intermediate ranges.2 While underlying CFTR mutations are strong predictors of pancreatic 
status, mutation class is a relatively poor predictor of lung disease phenotype. It is thought 
that in addition to the CFTR genotype, CFTR independent factors including CF  modifier 
genes and environmental factors influence the variability of CF lung disease and co -
morbidities.3, 4   
Part A of the study will focus on the clinical measures and molecular mediators that 
characterize different levels of CFTR activity (absent versus partial function) including a 
comparison to healthy control subjects in order to better understand the influe nce of CFTR 
function on phenotypic variability which may  aid in the future evaluation of emerging 
CFTR modulator therapies for individuals with CF. Biomarker analysis of biospecimens at 
the cellular, protein, metabolite and lipid levels will enable a bett er understanding of CF and 
CFTR influence on phenotype. Serial measurements over 3 months will allow for the 
assessment of the reproducibility and stability of biomarker, clinical and physiological 
profiles that can improve the ability to detect associatio ns with clinical phenotypes.  
1.1.1 Gastr ic pH (pH Pill) Sub-Study Rationale  
The role of CFTR as a regulator of bicarbonate secretion is an old concept that is being 
increasingly appreciated in recent years.  With the availability of a new minimally invasive 
tool, we have an extraordinary chance to study gastrointestinal pH in patients with CF in a 
multicenter manner. CF is associated with pancreatic insufficiency (PI) in the majority of 
patients, although 10 -15% may remain pancreatic sufficient (PS).  Although no t absolute, 
patients with CFTR mutations in Classes I -III are more likely to be PI than those with class 
IV and V mutations .5  CF-PI patients have been shown to have inadequate acid 
neutralization of the duodenum following direct pancreatic stimulation with intravenous 
secretin and have been shown to have delayed alkalinization of the proximal duodenum 
using an ingested diagnostic pill that wirelessly transmits pH data  (“pH pill”) .6, 7  CF-PS 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 9 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  patients do not have overt steatorrhea, but they have abnormal bicarbonate and flui d 
secretion responses to direct pancreatic stimulation with intravenous secretin .8, 9  A pH pill 
test will be con ducted in a subset of enrolled Cohort 2 and 3 subjects to evaluate whether 
these gradations in bicarbonate secretion (and thus CFTR function) between CF -PI and CF -
PS  patients can be detected using an ingestible pH pill.  
1.2 Part B CORE Study Rationale  
Develop ment of CFTR -targeted drugs represents a new era in CF treatment, one that is 
expected to revolutionize the care of CF patients in a profound way. CFTR modulators 
specifically target disease -causing CFTR mutations, with the aim of restoring protein 
functio n towards normal levels. To date, CFTR ‘potentiators’, which open the mutant CFTR 
channel and augment the activity of the protein at the plasma membrane, have had the most 
success in clinical trials. A landmark phase II trial of the CFTR potentiator ivacaf tor 
(Kalydeco™, Vertex Pharmaceuticals, Cambridge, MA) studied in 40 CF patients with at 
least one copy of the G551D mutation, a class 3 gating mutant, demonstrated impressive 
improvements in CFTR activity, detected by nasal potential difference (NPD) and sweat 
chloride testing, resulting in significant changes in lung function.10  This trial was rapidly 
followed by two pivotal phase III trials in which ivacaftor t reatment led to rapid, dramatic, 
and sustained improvements in lung function, weight, quality of life, and measures of CFTR 
function, and reductions in pulmonary exacerbations.11, 12  As a result, in 2012, the U.S. 
Food and Drug Administration (FDA) approved ivacaftor for CF patients ages 6 and older 
with the G551D mutation. Recently, ivacaftor received FDA approva l for CF patients with 
other non -G551D class III gating mutations. It is anticipated that ivacaftor therapy alone 
may benefit approximately 15% of the U.S. CF population.  In a Cystic Fibrosis Foundation 
Therapeutics  (CFFT ) led post -approval study termed t he “G551D Observational Trial 
(GOAL Study)” efficacy of ivacaftor was confirmed in CF patients with the G551D 
mutation, and additional information was gleaned from the evaluation of biomarkers related 
to CFTR activity; in addition, a robust biospecimen rep ository was formed, and is now 
being accessed by a variety of CF investigators.  
The next class of CFTR modulators in development and clinical trial testing are ‘correctors’ 
of F508del CFTR trafficking defects which work by increasing F508del CFTR protein at 
the plasma membrane. Vertex Pharmaceuticals has developed two F508del correctors that 
have advanced to clinical trials (VX -809 or lumacaftor, and VX -661). Preclinical testing has 
shown that combining the CFTR corrector lumacaftor with the potentiator iv acaftor leads to 
enhanced F508del CFTR activity relative to lumacaftor alone .13  Preliminary results from 
phase I II trials evaluating the combination therapy of lumacaftor and ivacaftor were recently 
released and indicated a modest improvement in lung function and an approximately 33% 
decrease in the rate of pulmonary exacerbations.14  Combination therapy with a CFTR 
corrector and pot entiator, if successful, has the potential to benefit approximately 80% of 
the U.S. CF population.  
The regulatory approval of lumacaftor /ivacaftor for the treatment of CF provide s an 
unprecedented opportunity to explore the clinical consequences of CFTR co rrection, 
complementing the previous GOAL study, while also examining a population expected to 
experience a less robust effect.  The results could offer new insights into the most relevant 
biomarkers sensitive to this pathway (providing a path forward towa rds the discovery and 
characterization of other biomarkers), while also lending insight into the mechanistic basis 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 10 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  underlying CF pathogenesis and how this is impacted by corrector -potentiator therapy.  By 
collecting blood, urine, sputum and stool samples a nd sweat chloride values, coupled with 
clinical parameters in a prospective fashion, we will enable significant research towards 
identifying and characterizing new and improved biomarkers of CF disease progression, 
including several exploratory outcome mea sures central to the CFTR defect and linked to 
disease activity and expression.   
Subjects co -enrolled in the Part B CORE study and the CFFT  funded  Prediction by 
Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study will be asked 
to share their data from this study with the PUSH study principal investigators to further 
evaluate the impact of lumacaftor /ivacaftor therapy on incide nce of CF -related liver disease .  
 
1.2.1 Exploratory Respiratory Outcome Measures  
1.2.1.1  Lung Clearance Index Rationale  
Spirometric measures, such as forced expired volume in one second (FEV1), have 
traditionally been used in the assessment of CF lung disease due to their direct correlation 
with morbidity and mortality15 . However, FEV1 tends t o remain within normal limits in a 
high percentage of patients, despite radiographic evidence of airway damage .16  This is 
likely due to the fact that these meas ures are primarily influenced by resistive changes in the 
large airways and thus not reflective of the patchy distribution of small airway pathology 
characteristic of early CF lung disease. The LCI, as measured by multiple breath washouts, 
reflects global ventilation inhomogeneity and as such is a highly sensitive marker for early 
obstructive lung disease .17-19  Furthermore, LCI is more sensitive than other mea sures of 
lung function in detecting structural changes identified by high resolution CT imaging .20-22  
Importantly, LCI tracks from preschool to school -age an d was found to precede subsequent 
abnormalities in spirometry indices23 and is independent of patient effort.  
Previous studies using interventions such as hypertonic saline and dornase alfa have 
demonstrated that fewer number of  CF subjects are required to detect a treatment effect 
using LCI in comparison with spirometric measures .24, 25  This was supported by a 
multicenter study with ivacaftor in CF patients carrying at least one G551D allele; where 
LCI improved significantly in ivacaftor treated patients .26  Post-hoc analyses showed that 
the number of subjects required to demonstrate a treatment effect was about 1/3 of that 
required for a study using FEV1 as an outcome measure.  Multiple breath washout (MBW) 
testing s will be performed in a subset of subjects enrolled in the Part B CORE study to 
evaluate the suitability of LCI as an outcome measure to detect and track treatment effects 
in patients receiving CFTR directed pharmacotherapy.  
1.2.1.2  Fractional Exhaled Nitric Oxide (FENO)  
Nitric Oxide (NO) is a complex signaling molecule produced by airway cells that regulates 
several processes including ciliary activity, ion transport, inflammation, and vascular 
tone.27, 28  The fraction of exhaled nitric oxide (FENO) is an established test to monitor the 
concentration of NO derived from the lung.  It is commonly used to monitor disease status 
in asthma, where it is typi cally elevated in the context of eosinophilic inflammation. 
Exhaled NO is extremely low in patients with primary ciliary dyskinesia (PCD), and nasal 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 11 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  eNO is a recently validated biomarker of ciliary activity for the diagnosis of PCD .27, 28  
FENO is also reduced in CF patients with normal lung function compared to non -CF 
controls, and it demonstrates an inverse corre lation with the lung function tests such as 
FEV1 and the lung clearance index .29, 30  It is unclear why FENO  is reduced in CF, but 
hypotheses include trapping of locally produced NO in the thick mucus blanket 
characteristic of the CF airway, decreased production by deficient nitric oxide synthase, 
increased NO consumption, or defects in ciliary function .27-32  Thus, exhaled NO may serve 
as a marker of ciliary function and secondarily mucociliary clearance in the context of CF. 
Recently we examined the fraction of exhaled n itric oxide (FENO) in a cohort of CF 
patients admitted for treatment of pulmonary exacerbations, and in a second cohort of CF 
patients with gating mutations who were candidates for ivacaftor therapy.  We examined 
FENO reproducibility, intra -subject and int ersubject variability, correlations with lung 
function, and relationships to concomitant therapies. In the second cohort we examined 
FENO, FEV1, weight and body mass index before and after four weeks of ivacaftor 
treatment (150 mg every twelve hours).  The  results support the hypothesis that changes in 
FENO can reflect restored CFTR function in CF patients, and due to its ease of 
measurement, availability of standardized equipment and procedures, and its direct 
relationship to ciliary function in PCD, we hy pothesize that FENO could potentially serve 
as a novel biomarker reflecting restored CFTR activity in the lower airways.  FENO testing 
will be performed in a subset of subjects enrolled in the Part B CORE Study to evaluate the 
suitability of FENO as an out come measure to detect and track treatment effects in patients 
receiving CFTR directed pharmacotherapy.  
1.2.1.3  Mucociliary Clearance (MCC)  
A current hypothesis for the pathogenesis of cystic fibrosis (CF) lung disease suggests that 
CFTR dysfunction leads to imbal anced ion transport, with reduced Cl-/HCO3- secretion 
through CFTR and accelerated Na+ absorption through the epithelial sodium channel 
(ENaC) .33, 34  Together, these changes in ion transport may deplete the airway surface liquid 
(ASL) lining fluid and dehydrate luminal mucus secretions.  Evidence supporting this 
hypothesis comes both from in vitro  and animal experiments, where the critical influence of 
ASL hydration on mucus transport has been clearly elucidated . 35, 36  In vivo , we have shown 
that bronchoscopically collected secretions from CF toddlers are abnormally concentrated, 
as indexed by % solids measurements, and progressive dehydration is observed in older 
patients with more advanced disease (unpublished d ata).  M easurements of MCC in CF 
patients using inhaled radiolabeled particles and gamma scintigraphy are also clearly 
abnormal, with marked slowing of clearance from the peripheral lung compartment , and in 
response to cough37, 38 the link between CFTR function and MCC was strengthened by a 
sub-study conducted within the GOAL Study.  Twenty -one patients with the G551D 
mutation at four study sites had MCC measured before and after beginning treatment with 
ivacaftor.  One month after starting therapy, MCC was markedly improved.  No additional 
increase (or decrement) in MCC was observed after 3 months of treatmen t, demonstrating a 
sustained and reproducible response.  Quantitatively, these sustained effects on MCC were 
similar to those previously measured acutely after inhaling hypertonic saline.  Perhaps most 
importantly, the most impaired regions of mucus cleara nce in the peripheral lung were 
markedly improved to a degree that has not been achievable through any inhaled therapy.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 12 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  It is clear that adequately restoring CFTR function in the lung yields profound clinical 
improvements in patients with CF.  As we develo p new therapies aimed at improving the 
function of delF508 -CFTR and other mutations, we unfortunately have few biomarkers that 
directly report on CFTR function in the lung, other than FEV 1.  While large changes in 
sweat chloride were observed with ivacafto r treatment in patients with G551D -CFTR, this 
biomarker has shown only small responses to treatment in patients homozygous for 
delF508 -CFTR, despite improved lung function.  Having a “pulmonary biomarker” that 
accurately and quantitatively reflects improve d CFTR function in the lung could provide a 
huge benefit to drug development by reducing the size of trials needed to make early 
evaluations of drug efficacy.  Evidence for the close association between CFTR function 
and MCC suggests that this assay may be  ideally suited for this purpose.  MCC testing will 
be performed in a subset of subjects enrolled in the PART B CORE  Study to  evaluate the 
utility of MCC as a biomarker in patients that are likely to have “partial” restoration of 
CFTR function ( i.e., less than that achieved with ivacaftor in G551D patients).  The 
resulting data will begin to define the relationship between MCC and clinical responses to 
CFTR modulator therapy, in conjunction with the previously mentioned GOAL data, while 
also helping us to u nderstand the “sensitivity” of MCC to these drug effects.   
1.2.2 Exploratory Gastro -Intestinal and Glucose -Insulin Outcome Measures  
1.2.2.1  Small Intestinal Bacterial Overgrowth (SIBO) (Breath Hydrogen Test)  
CFTR  is expressed throughout the GI tract, with CFTR mRNA le vels highest in the 
duodenum, including high expression in the pancreatic duct and mucus secreting Brunner's 
glands .39, 40  Duodenal bicarbonate is secreted via a CFTR -assisted chloride -bicarbonate 
exchange process and an electrogenic secretion of bicarbonate via a CFTR conductance 
pathway .41  Bicarbonate is also essential to the functioning of naturally –occurring 
antimicrobials; decr eased CFTR -mediated bicarbonate secretion may underlie dysbiosis.  
The defensins lysozyme and lactoferrin have decreased ability to kill bacteria at higher  
pH42. Our current understanding of the role of CFTR in the pathophysiology of dysbiosis in 
CF has been facilitated by studies using the CF mouse model.  Analysis of bacterial 16S 
ribosomal genes has been used to classify the intraluminal bacteria of the wild ty pe and CF 
mice. There was reduced species diversity in the CF intestine, with more than 90% of the 
microbes belonging to the Enterobacteriac eae family.  Also, about 6% of the bacteria in CF 
mice were Clostridium perfringens, which was not detected in the w ild type animals .43  A 
reduction in whole gut species diversity as measured by stool sampling is seen in humans 
with CF and distinguishes childr en with CF from those without CF .44, 45  A decrease in 
beneficial and abundance of potentially harmful  species was found in F508del homozygotes 
and those classified with greater disease severity status with CF, suggesting a link among 
CFTR mutations and shifts in fecal microbiota .46  Small intestinal bacterial overgrowth 
(SIBO), is dysbiosis of the upper intestine.  SIBO produces toxic byproducts and 
metabolites that can lead to enterocyte damage, malabsorption and malnutrition with 
diarrhea, abdominal distension,  flatulence, steatorrhea, macrocytic anemia, and weight 
loss47  SIBO has been seen in up to 30 -55% of patients with CF .48, 49  Although many 
factors can cause SIBO, defective bicarbonate secretion from CFTR dysfunction likely 
plays a central role in dysbiosis in the GI tract. Decreased dysbiosis would be expected with 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 13 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  improvements in CFTR function and should be associated w ith improvements in nutritional 
and abdominal symptoms and signs in patients with CF.  
Breath testing can identify dysbiosis in the proximal GI tract.   Breath testing will be 
performed in a subset of subjects enrolled in the Part B CORE study to evaluate if 
improvement in CFTR function can be demonstrated by examining the prevalence of SIBO 
before and after taking the combination of ivacaftor and lumacaftor.  
 
1.2.2.2  Gastro -Intestinal Inflammation (Fecal Calprotectin)  
The pathophysiologic triad of obstruction, inf ection and inflammation can be seen in the 
intestinal tract as well as in the airways.  Although the exact underlying mechanism of GI 
tract inflammation is unknown, dysfunctional CFTR is thought to be the inciting factor .50   
Endoscopic lavage of the CF small intestine showed increased levels of inflammatory 
markers in the lumen .51  A conventional endoscopic study showed that the CF duodenum 
was morphologically normal but there were increased levels of several inflammatory 
markers in biopsied tissue .52  More recent work using video equipped capsul e endoscopy 
showed that morphological abnormalities occur in the jejunum and ileum in more than 60% 
of CF patients which include edema, erythema, mucosal breaks, and ulcerations .53  That 
study also reported significant elevations of fecal calprotectin (a neutrophil secretory 
product) in many CF patients, consistent with intestinal inflammation. These inflammatory 
markers are seen in PS as well as PI patients, indi cating that CFTR dysfunction leads to “CF 
enteropathy” rather than inflammation being caused by local irritation from pancreatic 
enzyme replacement therapy .54 
Inflammation is a feature of intestinal as well as airway disease.  Fecal calprotectin, a 
neutrophil secretory product indicative of GI inflammation, is elevated in patients with 
CF.50  Calprotectin is well correlated with colonic inflammation but appears less rel iable for 
inflammation in the proximal GI tract .55  In one study in patients with CF, calprotectin did 
not correlate with presumptive small intestinal in flammation resulting from SIBO .56  
However, after treatment of whole -gut dysbiosis with probiotics, calprotectin levels 
decreased suggested improvements in int estinal inflammation .57  A subset of subjects 
enrolled in the Part B CORE study will provide fecal samples for fecal calprotectin.  
1.2.2.3  Gastric pH Rationale (pH Pill)  
The role of CFTR as a regulator of bicarbonate secretion is an old concept that is being 
increasingly appreciated  in recent years.  With the availability of a new minimally invasive 
tool, we have an extraordinary chance to study gastrointestinal pH in patients with CF in a 
multicenter manner. In CF patients with the G551D mutation, ivacaftor potentiates CFTR -
mediated  chloride secretion and leads to improved lung function and nutritional status .11  As 
part of the GOAL study, when subjects had GI pH measured using a pH pill befo re and after 
taking ivacaftor, bicarbonate secretion in the proximal GI tract improved, normalizing 
duodenal pH more efficiently .58  pH pill testing will be performed on a subset of subjects 
enrolled in the Part B CORE study to determine whether combination therapy with ivaca ftor 
and lumacaftor can achieve a similar degree of improvement in GI tract bicarbonate 
secretion in CF patients who are homozygous for the F508del mutation . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 14 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  1.2.2.4  Insulin Secretion (Oral Glucose Tolerance Test)  
Cystic fibrosis related diabetes (CFRD) is charact erized by progressive insulin 
insufficiency. It is extraordinarily prevalent in the CF population, occurring in 15 -20% of 
adolescents and, eventually, more than half of adults .59  Few of the remaining patients have 
completely normal glucose metabolism; even those with normal fasting and 2 -hour OGTT 
glucose levels typically have mid -OGTT glucose elevation (indeterminate glycemia) and 
have defective acute ins ulin secretion in response to intravenous glucose .60  While CFRD 
does not usually develop before puberty, it has its roots in childhood and glucose 
intolerance is common in 6 -9 year old children with CF .61  In childhood, CF patients are 
able to compensate for this defect because their b eta-cell mass is largely intact. As islets are 
lost over time due to exocrine fibrosis and as chronic, unrelenting beta -cell stress occurs due 
to inflammation, oxidative stress and recurrent infection, the impact of CFTR on insulin 
secretion becomes more c ritical.  
We postulate that CFTR plays a small but important role in insulin secretion.  A pilot study 
in five CF patients with the G551D CFTR mutation that measured insulin secretion before 
and 1 month after initiation of ivacaftor therapy provided prelimi nary evidence that drugs 
that improve CFTR function may increase insulin secretion in CF.  After 1 month of 
ivacaftor therapy, the insulin response to oral glucose improved by 66 -178% in all subjects 
except the one with long standing diabetes (p=0.07).  While childhood may be the ideal 
time to intervene (with the hope of establishing a healthy “bank” of fully functional beta 
cells which are better able to withstand the metabolic stresses of CF that escalate over time) 
further data needs to be gathered in ad ults before studying children.  Longitudinal 
assessment of a greater number of subjects with CF is necessary to determine whether early 
correction of CFTR could delay or even prevent diabetes.  Oral glucose tolerance testing 
will be performed in a subset o f subjects enrolled in the Part B CORE study to examine the 
role of CFTR in human insulin secretion, potentially opening the way for novel diabetes 
therapies and for prevention or at least amelioration of diabetes in CF.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 15 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  2 RISK AND BENEFIT ASS ESMENT  
As an o bservational study there is no anticipated direct benefit to subjects. The risks are 
associated with specific procedures.  
 
CORE  Study Procedures (Part A and Part B) : 
 
The risks from CORE  Study procedures are minimal and include:  
 Potential discomfort and b ruising from blood draws  
 Potential skin irritation from sweat chloride testing  
 Potential for increased coughing or wheezing associated with sputum induction.  For 
this reason, it is standard practice to administer a bronchodilator (e.g., albuterol) 
prior t o beginning the sputum induction procedure.  
 Potential discomfort during the nasal epithelial cell procurement  
 
Respiratory Sub - Study Procedures :  
 
MBW  Test: The instrument to be used for the MBW test is the Exhalyzer D by Eco Medics 
AG (Duernten, Switze rland).  There is a very small risk of hyperventilation, which is 
minimized because each breath will be visualized on the computer screen in real time and 
the exhaled gases are monitored. Rarely with hyperventilation there may be dizziness or 
fainting.  
 
FEN O Test : FENO is a non -invasive test commonly performed on asthma patients. There 
are no significant risks.  
 
MCC Testing : The following complications could result from inhalation of nebulized 
aerosols:   cough, shortness of breath, hoarseness, throat irritat ion, temporary decrease in 
lung function measurements, wheezing and decrease in oxygen saturation.  
The MCC procedure entails exposure to some radiation. The amount of radiation dose 
received during the study (2 MCC scans)  is approximately 89 millirem. The risk from the 
radiation dose received from this procedure is too small to be detected , but is significantly 
less than the radiation dose received from the natural environment over the course of 1 year 
(~300 millirem).  
Gastro -Intestinal/Glucose -Insulin Sub-Study Procedures : 
pH Pill Test : The SmartPill® has been approved for use by the FDA for the evaluation of 
gastric motility disorders, specifically delayed gastric emptying and chronic constipation.  
Medical problems or technical problems with the wireless m otility capsule  (SmartPill) can 
occur. The capsule may fail to empty from the stomach or may fail to be expelled from the 
GI tract.   
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 16 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  In previous studies with 326 non -CF adult patients with functional gastrointestinal 
problems, a total of 28 adverse events  were reported: 19 were not device related, 7 were 
probably not device related, 1 was possibly related and one was definitely related. In the AE 
that was definitely related, the capsule failed to empty the stomach after 9 days in a patient 
who was known to  have gastroparesis.  The patient was treated with polyethylene glycol 
and the capsule was passed within 24 hours. In post -marketing reports, there have been 20 
reported instances of capsule retention in approximately 6000 capsule shipments.  Of these, 
6 required endoscopic removal and the remainder resolved with la xative therapy.   The 
SmartPill  has been tested in two studies that included 41 tests on 34 individuals with CF .  
There were no adverse events and no instances of delayed capsule  expulsion. In th is study, 
there are several exclusion criteria to ensure that subjects with high risk of capsule retention 
are not included to reduce the likelihood of a subject experiencing these types of adverse 
events.  
If the capsule has not entered the colon or been evacuated with stool after 14 days,  a 
consultation with a clinician for appropriate follow -up is required . 
 
Breath Hy drogen Test: Breath hydrogen testing is a non -invasive test with no significant 
risks.  
Oral Glucose Tolerance Test : Risks of the oral gluc ose tolerance test procedure include 
discomfort and/or bruising related to placement of an IV port or blood draws.  There is also 
a risk  of lightheadedness during the test from not eating.  Subjects will be provided with a 
snack upon completion of the test  to minimize this risk.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 17 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  3 STUDY OBJECTIVES  
3.1 Primary Objective  
The primary objective of Part A is to  collect specimens  for the CFFT Biorepository , 
physiological  and clinical data to better understand the molecular mediators and profiles 
that characterize spe cific levels of CFTR activity in three different cohorts.  
The primary objective of Part B is to collect specimens for the CFFT Biorepository , 
physiological and clinical data on CF subjects who are homozygous for the F508del 
mutation before and after treatm ent with combination CFTR modulator therapy 
(lumacaftor/ivacaftor)  
3.2 Secondary Objectives  
A secondary objective for Part A is to determine if physiological and molecular profiles 
differ among those with mild versus severe lung disease in CF patients absent C FTR 
function (Cohort 3 ). 
A secondary objective of Part B of the study is to explore the impact of combination CFTR 
modulator therapy (lumacaftor/ivacaftor) on  various experimental outcome measures 
directly and indirectly relevant to CFTR modulation  in sub -sets of subjects . 
A secondary objective for both Parts A and B is to collect nasal epithelial cells from a sub -
set of subjects to develop a cell culture bank of sustained primary nasal epithelium for in 
vitro  analysis of disease mechanisms and response to experimental therapeutics.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 18 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  4 STUDY DESIGN  
4.1 Study Overview  
This is a two -part, multi -center, prospective longitudinal, exploratory study of biomarkers, 
clinical , and physiological profiles in CF.   
Part A  
In Part A , a cohort of non -CF control subjects and tw o cohorts of CF subjects, grouped by 
underlying level of CFTR function, will be studied .  Importantly, comparison with a non -CF 
control group will allow examination of CFTR -dependent biomarkers across the spectrum 
of CFTR activity (absent, partial, complet e).  
Part A  will consist of the Part A CORE Study and one optional sub -study (pH Pill). Refer 
to Study Schematics below and Schedule of Events in Appendices 1 and 2 for the specific 
visit schedule and procedures for each cohort. A subset of patients will u ndergo nasal cell 
procurement and storage.  
 Cohort 1 subjects (Controls) will be on study for up to 14 days with up to two visits.  
 Cohort 2 and 3 subjects (CF) will be on study for up to 3 months with up to three 
visits.  
Part B  
In Part B , Cohort 3 subjects who are homozygous for the F508del mutation and who are 
prescribed lumacaftor/ivacaftor will be further studied.  Part B  will also be expanded to 
allow for the enrollment of additional CF subjects homozygous for the F508del mutation 
who did not participate  in Part A.  (Refer to Study Schematics and Schedule of Eve nts in 
Appendi ces 2 and 3 ).  
 Subjects who enroll in Part B of the study will be on study for up to 12 additional 
months with up to five visits  during Part B . 
Part B  will consist of the Part B CORE Study and several optional exploratory outcome 
measure studies including:  
 Multiple Breath Washout (MBW)  
 Fractional Exhaled Nitric Oxide (FENO)  
 Mucociliary Clearance (MCC)  
 Gastro -intestinal Functional Testing  
 Glucose/Insulin Functional Testing  
 Small intest inal pH profile (pH Pill)  
Most study subjects will be asked to participate in an optional sub -study that includes a 
combination of these o utcome measures as noted below  ( refer  to Study Schematics for Part 
B and Schedule of Events in Appendix 3): 
 MBW/FENO with or without MCC   
 Gastro -intestinal and Glucose/Insulin Functional Testing (GIFT) with or without pH 
Pill 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 19 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  The sub -study available to the study participant will depend on the site where they are 
enrolled.  Up to 10 sites will be trained on the MBW and FE NO procedures and a sub -set of 
4 of these sites will also have the capacity to perform the MCC test.  Other sites will be 
trained on the GIFT and pH pill procedures.   
In addition, a  small subset of subjects  will undergo nasal cell procurement and storage.  
 
Study Schematics  

Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 20 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 21 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  5 CRITERIA FOR EVALUAT ION  
5.1 Part A  
5.1.1  Part A Primary Endpoints  
CORE  Study:  
The primary objective of Part A of the core study is to collect biospecimens for banking 
purposes; however the primary endpoint is sweat chloride by cohort.  
pH-Pill Sub -Study :  
 Small intestinal pH profile during the initial 30 minutes of small bowel transit, post 
gastric emptying by cohort.  
5.1.2 Part A Secondary Endpoints  
CORE  Study:  
 Within and between subject sweat chloride variance by cohort  
 Fecal elastase  and calprote ctin by cohort  
 Clinical measures: BMI , body weight , and FEV 1, by cohort  
 Sputum microbiome by CF cohort: Bacterial community indices (richness, evenness and 
diversity) and relative abundance of CF pathogens and anaerobes (including 
Pseudomonas aeruginosa, S taphylococcus aureus, Burkholderia cepacia, 
Stenotrophomonas maltophilia, Haemophilus influenzae, Prevotella) in sputum by CF 
cohort  and by lung disease severity in subjects  with absent CFTR function  
 Sputum markers of inflammation by CF cohort  and by lung disease severity in subjects  
with absent CFTR functio n: free neutrophil elastase activity, alpha 1 anti -trypsin 
(A1AT), secretory leukoprotease inhibitor (SLPI), IL -1β, IL -6, IL -8 
5.2 Part B  
5.2.1 Part B Primary Endpoints  
CORE  Study:  
The primary objective of Part B of the core study is collection of biospecimens for banking 
purposes and to serve as a platform for the sub -studies of lumacaftor/ivacaftor  mechanism; 
however the primary endpoint is change in FEV 1 between pre-treatment baseline and Visit 
7. 
GIFT Sub -Study : 
 Glucose Insulin Functional Testing Endpoints  
o Change in the area under the insulin curve during a standard 2 hour OGTT from 
Baseline to Visit 5  
o Change in the area under the c -peptide curve during a standard 2 hour OGTT 
from Baseline to Visit 5.  
 Gastro -intestinal Functional Testing Endpoints  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 22 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  o Percent with positive breath test by Fridge Criteria (fasting hydrogen>15 ppm, a 
rise of >10 ppm hydrogen over the baseline sample, or a doubling of baseline 
methane excretion) at Baseline and subsequent negative breat h test at Visit 5.  
 pH-Pill Sub-study : 
 Change in the small intestinal pH profile during the initial 30 minutes of small bowel 
transit, post gastric emptying from Baseline to Visit 5.  
MBW /FENO  Sub-Study:  
 Change in lung clearance index (LCI) from Baseline t o Visit 7  
 Change in FENO (ppm) from Baseline to Visit 5.  
MCC  Sub-Study:  
 Change in average whole lung clearance between 0 and 60 minutes (AUC60) from 
Baseline to Visit 5.  
5.2.2 Part B Secondary Endpoints  
CORE  Study:  
 Change in sweat chloride from Baseline to all post-baseline visits  
 Change in BMI and body weight from Baseline to all post -baseline visits  
 Change in sputum microbiome and markers of inflammation from Baseline to selected 
post-baseline visits . 
Other Evaluations for all Sub -Studies:  
 The core and sub -studies will be linked so that associations between primary and 
secondary endpoints from each sub -study and clinical parameters (e.g., spirometry, 
weight, and sweat chloride) may be explored.  
GIFT Sub -Study  
 Glucose/Insulin Functional Testing : 
o Percent in each  OGTT category (Section 8.1.4) at each visit, and change in 
category from Baseline to all subsequent visits 
o HbA1c at each Visit and change from Baseline to all subsequent visits  
o  For subjects on insulin therapy, insulin dose (units/kg/day) at each visit, and 
change in dose from Baseline to all subsequent visits. 
 Gastro -intestinal Functional Testing Sub -Study : 
o Percent with positive breath test by Fridge Criteria at Baseline and Visit 5  
o Mean fasting hydrogen levels (ppm) at Baseline and Visit 5 and change fr om 
Baseline to Visit 5 among those with measures at both time points ( i.e., positive 
breath test at Baseline).  
pH-Pill Sub -Study  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 23 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   Change in the small intestinal pH during the initial 120 minutes of small bowel transit, 
post gastric emptying  
 Change in time t o reach and sustain intestinal pH above 5.5 from Baseline to Visit 5  
 Change in the functional model of the pH curve from Baseline to Visit 5.  
MBW /FENO  Sub-Study  
 Change in LCI from Baseline to all subsequent visits  
 Percentage of subjects producing research quality measurements at all visits  
 Change in FENO from Baseline to all subsequent visits. 
MCC Sub -Study :  
The following changes will be examined between Baseline and Visit 5:  
 Change in average whole lung clearance between 0 and 30 minutes (AUC30) and 
betw een 0 and 90 minutes (AUC90)  
 Change in AUC60 in the peripheral lung compartment  
 Change in AUC60 in the central lung compartment  
 Change in cough clearance (average clearance measured between 60 – 90 minutes after 
isotope inhalation)  
 Change in whole lung cl earance measured through 24 hours.  
 
5.3 Safety Evaluations  (Part A and Part B)   
 Adverse events related to study procedures will be collected but not analyzed.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 24 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  6 SUBJECT SELECTION  
6.1 Study Population  
 See below for the specific eligibility criteria for Part A C ORE , Part B C ORE  and all sub -
studies.  
6.2 PART A  
6.2.1 Part A CORE  Study Non-CF Controls  (Cohort 1)  
6.2.1.1  Inclusion Criteria  
1. Written informed consent (and assent when applicable) obtained from subject or 
subject’s legal representative . 
2. Be willing and able to adhere to the st udy visit schedule and other protocol 
requirements . 
3. Male or fema le ≥ 12 years of age at Visit 1.  
4. Have a body mass index (BMI) of:  
 For subjects ≥ 18 years of age:  ≤ 30 kg/m2  
 For subjects 12 – 17 years of age: ≤ 95th percentile  
5. Be a non -smoker for ≥ 1 year prior to Visit 1  and have ≤ 10 pack -year history of 
smoking.  
6.2.1.2  Exclusion Criteria  
1. Presence of a condition or abnormality that , in the opinion of the Investigator , would 
compromise the safety of the patient or the quality of the data.  
2. Have at least one  known CFTR mutation.  
3. First degree relative of a patient known to ha ve CF , unless previous genetic analysis 
(testing must have includ ed BOTH mutations of the related CF patient)  indicates non -
carrier status .  
4. A history of any clinically significant medical illness or medical disorder that requires 
ongoing medical therapy, including (but not limited to) cardiovascular disease, 
neuromuscular disease, hematological disease including bleeding disorders, chronic 
respiratory disease (including persistent asthma), hepatic or gastrointestinal (GI) 
disease, neurological disease, neo plastic disease, renal diseases, or endocrine disorders 
including diabetes.   
5. Acute illness requiring any new prescription or over -the-counter treatment within 14 
days prior to Visit 1.  
6. Major or traumatic surgery within 12 weeks prior to Visit 1.  
7. For women  of child -bearing potential: a positive pregnancy test at Visit 1.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 25 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8. Initiation of any new chronic therapy within 28 days prior to Visit 1.  
9. Use of an investigational agent within 28 days prior to Visit 1.  
6.2.2 Part A CORE  Study CF Cohorts  
Note: Cohort 3 enrollme nt will be monitored throughout the study for genotype (F508del 
homozygous, heterozygous, and other), FEV 1 % predicted, and age distribution. Should 
imbalance occur, sites may be encouraged to recruit under -enrolling strat a and enrollment 
may close for cer tain genotype -FEV 1-age criteria.  
6.2.2.1  Inclusion Criteria  
1. Written informed consent (and assent when applicable) obtained from subject or 
subject’s legal representative.  
2. Male or female ≥ 12 years of age at Visit 1.  
3. Documentation of a CF diagnosis as evidenced by  one or more clinical features 
consistent with the CF phenotype and the following criteria:  
Cohort 2: (Partial  CFTR  Function CF)  
 Two mutations in the CFTR gene:   
o At least one allele must be a Class IV or V mutation with residual activity 
(Current updated list of  Class IV and V mutations  with residual activity  will 
be available on the study website ) 
o The second allele can be within any CFTR  mutation  class.  
 Sweat chlo ride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT) 
OR upon permission of the PROSPECT Investigator - Sponsors .   
Cohort 3: (Absent CFTR  Function  CF) 
 Two class I or II CFTR mutations ( Current update d list of Class I and II mutations 
will b e available on the study website ). 
4. Enrolled in the Cystic Fibrosis Foundation Patient Registry. Subjects may enroll in the 
Registry at Visit 1 if not previously enrolled.  
5. Clinically stable with no significant changes in health status within 2 weeks prior to 
Visit 1.  
6. Be a non -smoker for ≥ 1 year prior to Visit 1 and have ≤ 10 pack -year history of 
smoking.  
6.2.2.2  Exclusion Criteria  
1. Presence of a condition or abnormality that in the opinion of the Investigator would 
compromise the safety of the patient or the quality of the data.  
2. Any acute lower respiratory symptoms treated with oral, inhaled or IV antibiotics or 
systemic corticosteroids within the 2 weeks prior to Visit 1.  
3. Major or traumatic surgery within 12 weeks prior to Visit 1.  
4. For women of child -bearing potential: a positive pregnan cy test at Visit 1.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 26 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  5. Unable or unwilling to fast (including no enteric tube feedings) for at least 6 hours prior 
to each visit.  
6. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, 
azithromycin, TOBI®, Cayston®) within 4 w eeks prior to Visit 1.  
7. Use of an investigational agent within 28 days prior to Visit 1 . 
8. Use of chronic oral corticosteroids  within 28 days prior to Visit 1 . 
9. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of ≥ two 
antibiotics (oral, IV, and/or inhaled)  within 28 days prior to Visit 1 . 
10. Use of CFTR modulator therapy such as ivacaftor (Kalydeco®) within 28 days prior to 
Visit 1.  
11. History of lung or liver transplantation, or listing for organ transplantation.  
6.2.3 Part A pH Pill  
6.2.3.1  Additional Inc lusion Criteria  
1. Written informed consent for the sub -study.  
2. Male or Female ≥ 18 years of age at Visit 1.  
3. Meet eligibility criteria for Cohort 3 OR meet eligibility criteria for Cohort 2 AND have 
documented historical fecal elastase or serum trypsin within the normal range for the 
testing laboratory.   
4. Able to perfo rm the testing and procedures required for this study, as judged by the 
investigator.  
6.2.3.2  Additional Exclusion Criteria  
1. Unable to swallow a capsule.  
2. Does not routinely have a bowel movement at least every other day.  
3. Loose watery stools within the last two wee ks more than three times a day lasting more 
than 24 hours, or has had vomiting within the two weeks prior to Visit 2.  
4. Any upper or lower respiratory symptoms requiring treatment with oral, inhaled or IV 
antibiotics within 2 weeks prior to Visit 2.  
5. Unable o r unwilling to discontinue use of proton -pump inhibitors one week prior to 
Visit 2 until pH pill passage.  
6. Unable or unwilling to discontinue use of, calcium, aluminum or magnesium antacids 
one day prior to Visit 2 until pH pill passage.  
7. Unable or unwilling  to discontinue use of histamine 2 blockers two days prior to Visit 2 
until pH pill passage.  
8. Unable or unwilling to discontinue use of nocturnal enteric tube feedings the night prior 
to Visit 2 and until pH pill passage.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 27 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9. Unable or unwilling to discontinue use of any narcotic medications two days prior to 
Visit 2 until pH pill passage.  
10. History of fibrosing colonopathy, intestinal strictures, inflammatory bowel disease , 
bezoar , clinically significant gastroparesis requiring therapy or prior intestinal resect ion. 
11. Hospitalization for distal intestinal obstruction syndrome within 6 months prior to Visit 
2. 
12. Females who have a positive pregnancy test at Visit 2, are lactating or are not practicing 
(or willing to practice) a medically acceptable form of contracepti on from three days 
prior to Visit 2 until passage of the pH pill (acceptable forms of contraception: hormonal 
birth control, intrauterine device, barrier method plus a spermicidal agent or abstinence) 
unless surgically sterilized or postmenopausal.  
6.3 PART B  
6.3.1 Part B CORE   
6.3.1.1  Inclusion Criteria  
Cohort 3 Roll -over Subjects : 
1. Written informed consent (and assent when applicable) obtained from subject or 
subject’s legal representative.  
2. Two F508del CFTR  mutations . 
3. Physician decision to treat with lumacaftor/ivacaftor . 
4. Completion of at least Visit 1 and Visit 2 of Part A.  
5. Able to perform the testing and procedures required for this study, as judged by the 
investigator.  
Subjects who did not participate in Part A:  
1. Written informed consent (and assent when applicable) obtai ned from subject or 
subject’s legal representative.  
2. Male or female ≥ 6 years of age at Visit 4.  
3. Documentation of a CF diagnosis as evidenced by one or more clinical features 
consistent with the CF phenotype and the following criteria:  
 Two F508del CFTR mutations.  
4. Physician decision to treat with lumacaftor/ ivacaftor . 
5. Enrolled in the Cystic Fibrosis Foundation Patient Registry. Subjects may enroll in the 
Registry at Visit 4 if not previously enrolled.  
6. Clinically stable with no significant changes in health status within 2 weeks prior to 
Visit 4.  
7. Able to perf orm the testing and procedures required for this study, as judged by the 
investigator.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 28 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  6.3.1.2  Exclusion Criteria  
1. Presence of a condition or abnormality that in the opinion of the Investigator would 
compromise the safety of the patient or the quality of the data.  
2. Any acute lower respiratory symptoms treated with oral, inhaled or IV antibiotics or 
systemic corticosteroids within the 2 weeks prior to Visit 4.  
3. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme , hypertonic saline, 
azithromycin, TOBI, Cay ston) within 4 weeks prior to Visit 4.  
4. Use of an investigational agent within 28 days prior to Visit 4  
5. Use of chronic oral corticosteroids  within 28 days prior to Visit 4. 
6. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of  ≥ two 
antibiotics (oral, IV, and/or inhaled) , within 28 days prior to Visit 4. 
7. Use of CFTR modulator therapy such as ivacaftor (Kalydeco) within 28 days prior to 
Visit 4.  
8. History of lung or liver transplantation, or listing for organ transplantation.  
6.3.2 Part  B MBW/FENO Sub -Study  
6.3.2.1  Additional Inclusion Criteria  
1. Forced expiratory volume in 1 second (FEV1) consistently ≥ 30% of predicted value 
during the 6 months prior to Visit 4.  
2. Written informed consent for the sub -study.  
3. Able to perform the testing and procedur es required for this study, as judged by the 
investigator.  
6.3.2.2  Additional Exclusion Criteria  
None  
6.3.3 Part B MCC Sub -Study  
6.3.3.1  Additional Inclusion Criteria  
1. Male or female ≥ 12  years of age at Visit 4. 
2. Forced expiratory volume in 1 second (FEV1)  consistently  ≥ 30% of  predicted value 
during the 6 months prior to Visit 4.  
3. Written informed consent for the sub -study.  
4. Able to perform the testing and procedures required for this study, as judged by the 
investigator.  
6.3.3.2  Additional Exclusion Criteria  
1. Subjects who have had radia tion exposure within one year prior to Visit 4 that would 
cause them to exceed Federal Regulations by participating in this study (whole lung 
exposure >15 REM for adults; >1.5 REM for children).  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 29 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  2. Females who have a positive pregnancy  test at Visit 4, are l actating, or are not practicing 
(or willing to practice) a medically acceptable form of contraception (acceptable forms 
of contraception: hormonal birth control, intrauterine device, barrier method plus a 
spermicidal agent  or abstinence) from Visit 4 throu gh Visit 5 unless surgically sterilized 
or postmenopausal.  
3. Unable to adequately perform inhalation maneuvers needed for isotope deposition at 
Visit 4.  
4. Unable or unwil ling to discontinue the use of hypertonic saline and rhDNase 
(Pulmozyme ) for at least 12  hours prior to each MCC scan until completion of the 24 
hour-follow -up scan at Visits 4 and 5.  
6.3.4 Part B GIFT Sub -Study  
6.3.4.1  Additional Inclusion Criteria  
1. Written informed consent for the sub -study.  
2. Male or female ≥ 12  years of age at Visit 4. 
3. For insulin depende nt subjects, willing to hold all rapid -acting  insulin use for 6 hours 
prior to the OGTT test.  
4. For subjects on overnight enteric tube feedings , willing to hold the feeding for at least 8 
hours prior to  the GIFT procedures.  
5. Able to perform the testing and p rocedures required for this study, as judged by the 
investigator . 
6.3.4.2  Additional Exclusion Criteria  
1. Diagnosis of antibody proven type 1 diabetes.  
2. Treatment with metronidazole or rifamixin  within 2 weeks prior to Visit 4.  
3. Treatment with oral hypoglycemic agents  within 4 weeks prior to Visit 4.  
6.3.5 Part B pH Pill Sub -Study  
6.3.5.1  Additional Inclusion Criteria  
1. Written informed consent for the sub -study.  
2. Male or female ≥ 18 years of age at Visit 4. 
3. Able to perform the testing and procedures required for this study, as judged by the 
investigator.  
6.3.5.2  Additional Exclusion Criteria  
1. Unable to swallow a capsule.  
2. Does not routinely have a bowel movement at least every other day.  
3. Loose watery stools within the last two weeks more than three times a day lasting more 
than 24 hours, or has had vomiting within the two weeks prior to Visit 4.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 30 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  4. Unable or unwilling to discontinue use of proton -pump inhibitors one week prior to 
Visit 4 and Visit 5 until pH pill passage.  
5. Unable or unwilling to discontinue use of, calcium, aluminum or magnesium anta cids, 
one day prior to Visits 4 and 5 and until pH pill passage.  
6. Unable or unwilling to discontinue use of histamine 2 blockers two days prior to Visit 4 
and 5 and until pH pill passage.  
7. Unable or unwilling to discontinue use of nocturnal enteric tube feedings for at least 8 
hours  prior to Visits 4 and 5 and until pH pill passage.  
8. Unable or unwilling to discontinue use of narcotic medications for two days prior to 
Visits 4 and 5 and until pH pill passage.  
9. History of fibrosing colonopathy, intestinal strictu res, inflammatory bowel disease , 
bezoar , clinically significant gastroparesis requiring therapy or prior intestinal resection . 
10. Hospitalization for distal intestinal obstruction syndrome in the six months prior to Visit 
4. 
11. Females who have a positive pregna ncy test at Visit 4, are lactating or are not practicing 
(or willing to practice) a medically acceptable form of contraception from three days 
prior to Visit 4 until passage of the pH pill after Visit 5 (acceptable forms of 
contraception: hormonal birth co ntrol, intrauterine device, barrier method plus a 
spermicidal agent or abstinence) unless surgically sterilized or postmenopausal.  
6.4 Study Specific Tolerance for Inclusion/Exclusion Criteria  
Subjects who fail to meet one or more of the inclusion criteria or who meet any of the 
exclusion criteria will not be enrolled in this study. Waivers of any of the above study entry 
criteria will not be granted.  
6.5 Screen Fail Criteria  
Any consent ed patient who is excluded from the study enrollment  is considered a screen 
failure. All screen failures must be documented with the reason for the screen failure 
adequately stated . Subjects may be rescreened at a later date if it is anticipated that they will 
meet eligibility criteria.   
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 31 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  7 CONCURRENT MEDICATIO NS 
7.1 PART A   
7.1.1 Allowed Medic ations and Treatments  
Standard therapy for CF is allowed except for treatments noted in the exclusion criteria 
(Section 6.2) and as noted in the prohibited medications section below.    
A stable therapeutic regimen (including physiotherapy) between Visit 1  and Visit 3 is the 
goal. Ongoing chronic treatment with Pulmozyme , Cayston, TOBI, nebulized colistin, high 
dose ibuprofen, hypertonic saline, azithromycin, inhaled steroids, short and long acting 
bronchodilators and airway clearance is allowed.   Unless ot herwise medically indicated, 
subjects not using these therapies should not be started on them after Visit 1 or at any time 
during the study participation. Subjects that have been using them chronically should be 
encouraged to continue them throughout the e ntire study period (through Visit 3).   
7.1.2 Prohibited Medications and Treatments  
CORE  Study:  
 The use of any investigational therapies between Visits 1 and 3  
 The use of CFTR modulator therapy such as ivacaftor (Kalydeco) from 28 days prior 
to Visit 1 through Visit 3.  
 
pH Pill Sub -Study:  
 Proton pump inhibitors may not be taken for one week prior to pH pill ingestion 
(Visit 2)  until passage of pH pill  
 Histamine -2 blockers  and narcotic medications  may not be taken for two days prior 
to pH pill ingestion (Visit 2 ) until passage of pH pill  
 Calcium, magnesium or aluminum antacids may not be taken for one day prior to pH 
pill ingestion (Visit 2)  until passage of pH pill  
 Nocturnal enteric tube  feedings may not be taken for at least 6 hours  prior to pH pill 
ingestion (Visit 2 ) until passage of pH pill.  
7.2 PART B  
7.2.1 Allowed Medications and Treatments - Part B  
Standard therapy for CF is allowed except for treatments noted in the exclusion criteria 
(Section 6.3)  and as noted in the prohibited medications section below.  
7.2.2 Prohibi ted Medications and Treatments  
CORE  Study:  
No medications are prohibited during the study.  
MBW/FENO Sub -Study:  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 32 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  No medications are prohibited during this sub -study . 
 MCC Sub -Study:  
 Hypertonic saline and rhDNase (Pulmozyme) may not be taken for at least 12  hours 
prior to each MCC scan and until completion of the 24 hour follow -up scan at Visits 
4 and 5 . 
 Investigative therapies anticipated to have an effect on the mucociliary clearance are 
prohibited from 28 days prior to Visit 4 through Visit 5.  
GIFT Sub -Study:  
 Treatment with metronidazole and rifamixin  is prohibited from 2 weeks prior to 
Visit 4 until after the Visit 5 breath test . 
 Treatment with oral hypoglycemic agents from 4 weeks prior to Visit 4 until the end 
of the study.  
 All rapid -acting  insulin may not be taken for 6 hours prior to the OGTT test.  
 Nocturnal enteric tube feedings may not be taken for at least 8 hours prior to OGTT 
test (Visits 4, 5, 7 and 8).   
pH Pill Sub -Study:  
 Proton pump inhibitors may not be taken for one week prior to pH pill in gestion 
(Visits 4 and 5)  until passage of pH pill  
 Histamine -2 blockers and narcotic medications may not be taken for two days prior 
to pH pill ingestion  (Visits 4 and 5)  until passage of pH pill  
 Calcium, magnesium or aluminum antacids may not be taken fo r one day prior to pH 
pill ingestion (Visits 4 and 5)  until passage of pH pill  
 Nocturnal enteric tube feedings may not be taken  for at least  8 hours prior to pH pill 
ingestion (Visits 4 and 5 ) until passage of pH pill .  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 33 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8 STUDY PROCEDURES AND  GUIDELINES  
The procedures described below will be perfor med at the visits noted in the Schedule of 
Events (Appendices  1, 2 and 3 ) and in Section 9 .  
Prior to conducting any study -related activities, written informed consent and the Health 
Insurance Portability and Accou ntability Act ( HIPAA ) authorization must be signed and 
dated by the subject or subject’s legal representative.  If appropriate, assent must also be 
obtained prior to conducting any study -related activities.  
To participate in the optional DNA banking compon ent of this study, subject must have 
signed the informed consent indicating willingness to participate in the genomic component 
of the study. Refusal to give consent for this component does not exclude a subject from 
participation in the study.  
8.1 Clinical A ssessments  
8.1.1 Concomitant Medications  Review  
Part A CORE  Study:  
All concomitant medication and concurrent therapies will be documented as noted in the 
Schedule of Events .  Dose, route, unit, frequency of administration, indication for 
administration and dat es of medication taken within 30 days prior to Visit 1  through Visit 3 
will be captured.  
Part B CORE  Study:  
Only limited concomitant medications will be recorded during PART B.  Dose, route, unit, 
frequency of administration, indication for administration,  and dates of medication will be 
captured.  The use of the following medications from 30 days prior to Visit 4 through Visit 
8 will be recorded:  
 Oral, inhaled, or IV antibiotics  
 Lumacaftor/ivacaftor  
 Investigational therapies (Protocol number and treatment assignment will be 
recorded for open -label studies.  For blinded studies, the protocol number will be 
recorded; if the treatment assignment is known prior to database lock, th e 
treatment assignment will be added to the record.)  
 Key chronic respiratory ther apies (rhDNase, hypertonic saline, azithromycin)  
8.1.2 Demographics and CFF Registry ID  
Demographic information (date of birth, sex, race) will be recorded for all subjects. CF 
Registry number will be recor ded for participating CF subjects .    
8.1.3 Medical History  
Relevant medical history, including history of any current disease, other pertinent 
respiratory history , and information  regarding underlying diseases  will be recorded for all 
subjects  participating in Part A .  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 34 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8.1.4 Historic OGTT Result  
The most recent historic OGTT result (if available) should be reported as one of the 
following:   
Category  Fasting 
glucose  
(mg/dl ) 2hr glucose  
(mg/dl ) Notes  
 
Normal  <126 <140 All glucose levels < 200  
Indeterminate  <126 <140 Mid-OGTT glucose ≥ 200  
Impaired  <126 140-199   
CFRD FH - <126 ≥200   
CFRD FH+  ≥126   
8.1.5 Historic Fecal Elastase Result  
The most recent fecal elastase result prior to Visit 1 should be reported as mcg pancreatic 
elastase/g stool .  For subjects in Part A Cohor t 2 only,  if no fecal elastase result within 5 
years prior to Visit  1 is available, a fecal elastase test should be run locally and reported in 
the study database.  
8.1.6 CF Diagnosis  
Diagnosis date and genotype will be recorded for all participating CF subjects . 
8.1.7 Height and Weight    
Height and weight will be measured on the same scale and recorded as noted in the 
Schedule of Events. Subjects may remain in clothes (without shoes). A standing height will 
be measured and recorded.  
8.1.8 Menstrual Cycle Timing  
For females  of child -bearing potential, menstrual cycle timing will be  documented  (first day 
of last period ). 
8.1.9 Spirometry  
Spirometry will be performed in accordance with the current American Thoracic Society 
recommendations for the performance and interpretation of te sts for all participating CF 
subjects.    
If spirometry is performed at the same visit as sputum induction, the spirometry procedure 
should be performed in concert with the sputum induction procedure. Spirometry should be 
performed within 15 ±5 minutes of  administration of  the short -acting bronchodilator ( e.g., 
albuterol)  required for the induction procedure and prior to the induction procedure itself.  
If sputum induction is not being performed , short -acting bronchodilator ( e.g., albuterol)  
should still be a dministered prior to the spirometry procedure as noted above.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 35 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8.1.10  Clinical Status Review  
Clinical status  (e.g., stable, respiratory symptoms, recently treated with antibiotics)  will be 
reviewed  and documented  for all participating CF subjects  by the PI (or m edically qualified 
sub-investigator) . 
8.1.11     Adverse Events  
Only information regarding the occurrence of adverse events related to study procedures  
will be captured throughout the study. D uration (start and stop dates), grade, outcome, 
treatment and relation t o study procedure will be recorded on the case report form (CRF).  
8.1.12  FENO Measurement (MBW/FENO Sub -Study Only)  
The fraction of exhaled nitric oxide  (FENO ) is measured using an on -line 
chemiluminescence analyzer (various manufacturers acceptable).   Single bre ath on -line 
measurements are performed at a constant expiratory flow of 50 ml x min -1, (FENO  50) in 
accordance with current American Thoracic Society  standards . The mean of three 
measurements within 15% variation are used for analysis.  The procedure will b e performed 
at sites with required equipment and the capability of performing the procedure in 
compliance with  published ERS/ATS standards. 
8.1.13  MBW Measurement (MBW/FENO Sub -Study Only)  
The Exhalyzer D (Eco Medics, AG) will be used to assess the efficiency of ventilation 
distribution and gas mixing by measuring the rate of clearance of an inert gas from the lungs 
in compliance with Multiple Breath Wash SOP.  
During the test, subjects will be in an upright seated position and will use a mouthpiece and 
nose clip or face mask.  Subjects will be asked to breathe normally and a tight seal must be 
maintained on the mouthpiece throughout the test.  Each test takes about five minu tes.  
Subjects will do between three  and five tests with a 5-minute rest between them.  Subjects 
will be instructed not to drink carbonated beverages for 30 minutes before and between tests 
as the CO 2 may cause inaccurate results.  
MBW consists of following a tracer gas over two phases, a wash -in and a washout phase. In  
the wash -in phase, subject s will breathe room air through the mouthpiece connected to 
Exhalyzer D.  Subjects will be asked to take breaths until O 2 concentration on expira tion 
drops to below 17%.   After three  consecutive breaths in the acceptable CO 2 target range are 
reached, the subjects will start breathing 100% oxygen that comes from a hospital oxygen 
tank.  In the washout phase, subjects will be asked to breathe room air until the N 2 
concentration is 1/40th of the start concentration for three  consecutive breaths.   
8.1.14  MCC/CC Meas urement (MCC Sub -Study Only)  
A transmission scan (solid sheet containing Co57, placed in front of the body) of the 
subject’s lungs will be obtained .  Detailed instruction will be included in  a Study Specific 
Procedure .  
For each measure of MCC/CC, the sub ject will inhale an aerosol of sulfur colloid labeled 
with Tc99m [40 microcuries].  Inhalation will occur until ~40 μCi of radioactivity is 
deposited in the lungs of subjects and takes approximately two minutes.  An initial 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 36 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  deposition scan will then be rec orded and, as the subject remains seated in front of the 
gamma camera, continuous two -minute images will be recorded every 10 minutes for 90 
minutes to monitor particle clearance from the lung.  
During the first hour of imaging, subjects will be encouraged  to suppress spo ntaneous 
coughing so that cilia -driven clearance can be assessed.  From 60 –90 minutes, they will 
voluntarily cough through a peak flow meter, to achieve a total of 30 coughs during this 
interval, to assess cough clearance (CC).  Voluntary c oughs will be dispersed evenly during 
this interval, and the peak airflow rate of every fifth voluntary cough will be recorded and 
averaged.  Spontaneous cough frequency will be recorded throughout the imaging period.  
Subjects will return to the lab the f ollowing day for a 30 -minute continuous scan of residual 
lung activity at 24 hours (±6 hours) after the initial deposition scan . 
The images collected will be downloaded in dicom format  and sent to  UNC, Chapel Hill.  
8.1.15  3-Day Insulin Diary (GIFT Sub -Study Subje cts Only)  
Subjects will be requested to complete a daily diary to document  use of short and long term 
acting insulin  for three  days prior to the study visit.   
8.1.16  pH Pill  Ingestion (Part A and B pH Pill Sub -Study Only)  
The pH pill is a wireless motility capsu le that  houses sensors for pH, temperature, and 
pressure and transmits the sensed data at 434 MHz.  The pH pill  will be activated  by site 
staff and the subject will ingest the pH pill . Capsule signals are transmitted from within the 
GI tract and are captur ed by a receiving antenna in a portable receiver worn by the subject.  
After the subject has passed the pH pill  (as indicated by the temperature drop or loss of 
transmission signal on the receiver) or five days after pH pill  ingestion, the portable receiver  
will be mailed to the Women and Children’s Hospital (Buffalo, NY).  
NOTE : Subjects who participate in PART A pH pill sub -study do not need to repeat the 
procedure at Visit 4 if Visit 2 occurred within nine months prior to PART B Day 1.  
8.1.17  GI Symptom Assessme nt (pH Pill Sub -Study Only)  
An assessment of GI symptoms will be performed to determine if the subject meets the 
criteria to perform the pH Pill Sub -Study procedures.  
8.1.18  Abdominal Physical Examination (pH Pill Sub -Study Only)  
An abdominal physical examination  will be performed by either the investigator or a sub -
investigator who is medically qualified to perform the exam .   
8.1.19  Modified Symptom Sub-Scale of the CFQR  (pH Pill Sub -Study Only)  
A modified version of the Symptom  Sub-scale of the CFQR will be completed by the 
subject.    
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 37 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8.2 Clinical Laboratory Measurements  
8.2.1 Hematology  
Blood will be obtained and sent to each site’s clinical hematology lab for a complete blood 
count (hemoglobin, hematocrit, red blood cell count, white blood cell count, white blood 
cell differen tial, and platelet count) . 
8.2.2 Blood Chemistry Profile   
Blood will be obtained and sent to each site’s clinical chemistry lab for determination of 
BUN, creatinine, albumin, aspartate aminotransferase (AST/SGOT), alani ne 
aminotransferase (ALT/SGPT),  and gamma -glutamyl transferase (GGT) .  
8.2.3  Hemoglobin A1C   
Blood will be obtained and sent to each site’s clinical chemistry lab for determination of 
HbA1C levels.  (During Part B, HbA1C will only be performed on subjects enrolled in the 
GIFT sub -study).  
8.2.4 Pregnancy Test   
Urine will be collected from females who are of childbearing potential for a pregnancy test 
and tested in clinic according to site standard procedures .  
8.3 Research Laboratory Measurements  
Detailed instructions  for specimen collection, processing, storage an d shipping of samples 
will be provided in the Study Laboratory Manual.  
8.3.1 Macroduct Sweat Chloride Test  
The Macroduct® collection system (Wescor, Logan UT) will be used according to TDN 
SOPs to collect sweat to evaluate sweat chloride.  Sweat chloride levels will be evaluated at 
the CFFT TDN Center for Sweat Analysis located at Children’s Hospital Colorado (Aurora, 
CO).   
8.3.2 Induced Sputum Collection and Processing  
Sputum will be collected by sputum induction in compliance with current CFFT TDN 
SOPs.   
For safety  reasons , the induction procedures will only be performed for subjects who meet 
the following criteria on the day of the induction : 
 FEV 1 ≥ 40% predicted  
 No history of massive hemoptysis within 72 hours of the visit   
 Able to tolerate the sputum induction procedure  
If the subject is not able to undergo the sputum induction procedure (i.e. , due to FEV 1 < 
40% predicted,  massive hemoptysis within 72 hours of the visit, or otherwise unable to 
tolerate the procedure), an expectorated sputum sample may be collect ed, provided the 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 38 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  subject is able to spontaneously expectorate a good quality sputum sample (defined as a 
minimum 0.5  mL volume of sputum with visible mucus plugs).  
Collected sputum s pecimens will be processed at the CFFT TDN Center for Biochemical 
Markers  (CBM) located at Children’s Hospital Colorado (Aurora, CO) and used as noted 
below : 
 Sputum inflammatory mediator  levels  (e.g., A1AT, SLPI, IL -1β, IL -6, and IL -8), 
analysis at CFFT TDN CBM at Children’s Hospital Colorado  
 Sputum microbiome  analysis  at CFFT  TDN CBM at Children’s Hospital 
Colorado  
 Processed aliquots will be banked  at CFFT Biorepository  for future analysis   
8.3.3  Breath Test (GIFT Sub -Study Only)  
The EasySampler® Breath Test Collection Kit  will be used to collect breath samples to 
evaluate gastro -intestinal function. Breath  samples  will be collected prior to  and at 15, 30, 
45, and 60 , 90 and 120 minutes post glucose ingestion .  Samples will be sent to Kaleida 
Health Gastroenterology Laboratory in Buffalo , NY  for laboratory testing analysis .. (Note: 
all times are ±5 minutes to accommodate both the breath test and blood sampling)  
8.3.4 OGTT (GIFT Sub -Study Only)  
A standard  two-hour OGTT will be performed with blood draws performed  prior to  and at  
30, 60, 90, and 120 minutes post glucose ingestion .  Approxima tely 20 total mL of blood 
will be collected. Samples will be sent to  Fairview University Diagnostic Laboratories in 
Minneapolis, MN  for determination of glucose, insulin and c -peptide levels and analysis 
and calculation of glucose tolerance and metabolic status .(Note: all  times are ±5 minutes to 
accommodate both the breath test and blood sampling).  
Prior to the test:  
 Subjects who are currently taking insulin should  withhold rapid -acting  insulin for 6 
hours prior to the test  
 Subjects on nigh t-time feeding s should hold the feeding (including enteric tube  
feedings) at least 8 hours prior to the test.  
8.3.5 Fecal Collection (Part A CORE  and GIFT Sub -Study Only ) 
Collection supplies and instructions will be provided for stool collection at home  as noted in 
the Schedu le of Events . Subjects will be instructed to collect and freeze the samples  at home 
and bring to the clinic at their next study visit .  
Collected s tool samples will be used for:  
 Fecal Calprotectin analysis at the CFFT TDN Center for Biochemical Markers 
located at Children’s Hospital Colorado (Aurora, CO).  
 Banking at the CFFT Biorepository  for future analysis , including fecal elastase . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 39 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8.3.6 Nasal Epithelial Cells Procurement  
Nasal epithelial cells will be collected  in compliance with a Study Specific SOP  from 
subjects who signed the informed consent indicating willingness to participate in the 
genomic com ponent of the study .  
Nasal epithelial cells will be process ed and stored at a CFFT designated lab. 
Note: Nasal cells are only to be collected one time and the t iming of collection is not visit 
specific.  
8.4 Specimens for Long -Term Biorepository Storage  
Instructions for specimen collection, processing, storage and shipping of samples will be 
provided in the Study Laboratory Manual.  
The following specimens will be co llected as per the Schedule of Events and stored at the 
CFFT Biorepository : 
 Serum, plasma , and buffy coat ( WBC ):  Approximately 13.5 ml of blood will be 
collected . WBC specimen s will be stored  only if DNA consent is obtained .  
 Urine:  Approximately  10 mL of urine will be collected . 
 Stool :  As noted in above  Protocol Section 8.3. 5,  a portion of collected stool will be 
sent to the CFFT B iorepository  
 Processed Induced Sputum:  As noted in above  Protocol Section 8.3.2  after the 
sputum has been processed, aliq uots will be sent to the CFFT Biorepository.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 40 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9 EVALUATIONS BY VISIT  
The evaluations described below are organized separately by each study the subject has 
consented to participate in.   
 Section 9.1  Part A CORE  Study – Normal Controls  
 Section 9.2  Part A CORE Study  – CF Subjects  with or without pH Pill   
 Section 9.3  Part B CORE  Study   
 Section 9.4   Part B CORE  Study  plus MBW/FENO  
 Section 9.5  Part B CORE  Study plus MBW/FENO with MCC  
 Section 9.6  Part B CORE  Study  plus GIFT  
 Section 9.7  Part B CORE  Study  plus GIFT with pH Pill Sub -Study  
9.1 Part A CORE  Study – Normal Controls Only  
9.1.1  Visit 1 (Day  0) 
Note:  Subject should be fasting  (no solids or liquids with the exception of water) for 6 
hours prior to the visit . 
1. Review the study with the subject (subject’s legal  representative) and obtain written 
informed consent and HIPAA authorization and assent, if appropriate . (To ensure that 
the subject is fasting, consent may need to be obtained prior to the visit.)  
2. Assign the subject a unique subject  number . 
3. Record demogr aphics data .  
4. Record medical history . 
5. Record menstrual cycle timing (if female of child -bearing potential)  
6. Record concomitant medications.  
7. Review eligibility criteria to confirm eligibility.  
8. Measure and record height and weight.  
9. Obtain Macroduct sweat samp le. 
10. Collect blood  for: 
 clinical laboratory tests (hematology ) 
 banking  
11. Collect urine for : 
 pregnancy test (if female of child -bearing potential)  
 banking  
12. For sites with capability to collect nasal epithelial cells: Obtain nasal epithelial cells (if 
DNA consen t was obtained ). Note: t his is a non -visit specific procedure  that should be 
performed only once and at whichever visit is most convenient).  
13. Record any Adverse Experiences ( AEs) related to study procedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 41 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  14. Provide subjects with stool collection instructio ns and supplies .  
15. Schedule next visit . 
9.1.2 Visit 2 (Day  14 ±7 Days ) 
Pre-visit Reminder Call  (at least one day prior to visit)  
Remind subject : 
 Date/time of visit  
 Collect, freeze and bring stool sample to visit.  
 No solids or liquids with the exception of water  and no enteric tube  feedings at least 
6 hours prior to  visit 
Day of Visit:  
1. Obtain subject -collected stool (frozen)  
2. Record menstrual cycle timing (if female of child -bearing potential) . 
3. Record concomitant medications.  
4. Collect blood for banking.  
5. Collect urine  for: 
 pregnancy test (if female of child -bearing potential)  
 banking  
6. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at Visit 1 and if DNA consent was obtained .  
7. Obtain collect ed stool from subject  for research  laboratory tests  and banking.  
8. Record any AEs related to study procedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 42 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   
9.2 Part A CORE  Study – CF Subjects (with or without  pH Pill)  
Subjects who are prescribed lumacaftor/ivacaftor during Part A of the study will need to 
complete at minimu m Visits  1 and 2 before they can enroll in Part B. Visit 4 may occur up 
to 30 days prior to the planned start of lumacaftor/ivacaftor.  
A sub -set of subjects enrolled  in pH -pill Sub -study will have additional study procedures 
performed  in addition to the CORE Study procedures.  
9.2.1 Visit 1 (Day 0)  
Note:  Subject should be fasting  (no solids or liquids with the exception of water and no 
enteric tube feedings) for at least 6 hours prior to the visit . 
CORE  Study:  
1. Review the study with the subject (subject’s legal re presentative) and obtain written 
informed consent and HIPAA authorization and assent, if appropriate.  (To ensure that 
the subject is fasting, consent may need to be obtained prior to the visit.)  
2. Assign the subject a unique subject  number.  
3. Record demographi cs data and CFF Registry ID.  
4. Record medical history, CF diagnosis date, and genotype.  
5. Record most recent historic OGTT result if available.  
6. Record most recent historic fecal elastase result. For subjects in Cohort 2: if no 
historic result from within 5 ye ars is available, conduct test locally and record result.  
7. Measure and record height and weight.  
8. Perform clinical status review.   
9. Record menstrual cycle timing (if female of child -bearing potential)  
10. Record concomitant medications.  
11. Collect urine for:  
 pregnan cy test (if female of child -bearing potential)  
 banking  
12. Review eligibility criteria to confirm eligibility.  
13. Obtain Macroduct sweat sample.  
14. Collect blood for : 
 clinical laboratory tests (chemistry, hematology and HbA1C)  
 banking  
15. For sites with capability to co llect nasal epithelial cells: Obtain nasal epithelial cells (if 
DNA consent was obtained ). (Note: t his is a non -visit specific procedure  that should 
be performed only once and at whichever visit is most convenient).  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 43 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  16. Perform spirometry and sputum induction,  according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum  if possible)   
17. Record any AEs related to s tudy procedures.  
18. Provide subject with stool collection instructions and supplies .  
19. Schedule next visit . 
9.2.2 Visit 2 (Day 14  ±7 Days)  
Note:      If subject comes in with symptoms of a pulmonary exacerbation requiring 
treatment, is currently being or has recently  been treated for a pulmonary exacerbation  
reschedule the subject to return for the study visit two weeks after completion of the acute 
systemic therapies.  
Pre-visit Reminder Call  (at least one day prior to visit for non -pH pill subjects and one week 
prior  for pH pill subjects)  
Remind subject : 
 Date/time of visit  
 No solids or liquids with the exception of water  and no enteric tube  feedings  for at 
least 6 hours prior to  visit 
 Collect, freeze and bring stool sample to visit.  
Additional reminders f or pH Pill Su b-Study:  
 Discontinue proton pum p inhibitors for one week prior to visit 
 Discontinue h istamine -2 blockers and narcotic medications for two days prior to 
visit.  
 Discontinue c alcium, magnesium or aluminum antacids for one day prior to visit.   
 Abstain from al cohol for 24 hours . 
NOTE: Subjects participating in pH Pill sub -study should not have any liquids 2 
hours prior to the procedure and a total amount of water consumed during the 
fasting period should not exceed 6 oz of water.  
Day of Visit  
1. Obtain subject -collected stool (frozen)  
2. Measure and record height and weight.  
3. Perform clinical status review . 
4. Record menstrual cycle timing (if female of child -bearing potential)  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 44 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  5. Record concomitant medications.  
6. Obtain Macroduct sweat sample.  
7. Collect blood for : 
 clinical labo ratory tests (hematology)  
 banking  
8. Collect urine for : 
 pregnancy test (if female of child -bearing potential)  
 banking  
9. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albute rol) 
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
10. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at Visit 1 (and if DNA consent was obtained ). (Note: t his is a non -visit 
specific procedure  that should be  performed only once and at whichever visit is  most 
convenient ). 
11. Record any AEs related to study procedures.  
12. Provide subject with stool collection instructions and suppli es.  
13. Schedule next visit . 
Additional Procedure s for pH Pill Sub -study:  
14. Perform GI symptom assessment . 
15. Perform an abdominal physical exam . 
16. Confirm that the subject meets additional Visit 2 pH Pill eligibility criteria and has 
nothing by mouth except water at least  6 hours  prior  to visit before proceeding with 
Steps 1 7-24 below.  If the subject does not meet eligibility for participation in the pH 
Pill Sub -Study, proceed with all CORE  Study visits and procedures only.  
17. Have subject complete the modified sympto m sub -scale  CFQR.  
18. Turn on the radiofrequency detector, and then turn on the pH pill with the magnet. 
Record the pH Pill number in the source documents.   (Reminder: the radiofrequency 
detector needs to remain within 3 feet of the subject at all times.)  
19. Have  the subject drink 1.75 gm/kg (maximum 75 grams) of glucose (GlucoCrush) . 
20. Subjects should swallow their pH pill with the GlucoCrush.  Record the date and time 
that the pH Pill was swallowed in the source documents.   
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 45 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  21. Instruct the subject not to eat for an ad ditional 2 hours after their ingestion of the 
GlucoCrush , but to eat something after the 2 hours has elapsed.   If the subject is still 
in the clinic 2 hours after GlucoCrush ingestion , they should be provided with 30 g of 
carbohydrate . 
22. Provide the subjects  with instructions on the use of the radiofrequency  detector  (and 
review with them) . 
23. If applicable, remind subject to hold any enteric tube feedings until after the pH pill 
has passed.  
24. Provide the subject with the pre -paid mailer and i nstruct the subject t o send the 
radiofrequency detector and the return form  to Buffalo  in the pre -paid mailer as noted 
in the instructions.  
25. Remind the subject that you will be calling them within 24  hours.  
9.2.2.1  Contact 2B (Visit 2 + 1 Day ) 
CORE  Study:  
None.  
pH Pill Sub -Study :  
One ( 1) day after the ingestion of the pH pill : 
1. Confirm that the subject is using the device .  
2. Assess if any adverse events have occurred.  
3. Assess if the subject has passed the pH Pill.  (The radiofrequency detector will display 
an “X” ). 
4. Remind the subject to re turn the radiofrequency detector and the return form  to 
Buffalo as per the instructions .  
9.2.3 Visit 3 [Month 3  (90 days  ±30 days ] 
Note 1:      If subject comes in with symptoms of a pulmonary exacerbation requiring 
treatment, is currently being or has recently been treated for a pulmonary exacerbation  
reschedule the subject to return for the study visit two weeks after completion of the acute 
systemic therapies.  
Note  2:  Subjects who will be enrolling in Part B within 120 days  of Visit  2, may skip Visit 
3 and pr oceed to Visit 4.  
Pre-visit Reminder Call : 
 Date/time of visit  
 Collect, freeze and bring stool sample to visit.  
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 46 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   No solids or liquids with the exception of water  and no enteric tube feedings for at 
least 6 hours prior to  visit 
CORE  Study:  
1. Obtain subject -collected stool (frozen)  
2. Measure and record height and weight.  
3. Perform clinical status review.  
4. Record menstrual cycle timing (if female of child -bearing potential)  
5. Record concomitant medications.  
6. Obtain Macroduct sweat sample.  
7. Collect blood for : 
 clinical labo ratory tests (hematology)  
 banking  
8. Collect urine for : 
 pregnancy test (if female of child -bearing potential)  
 banking  
9. Perform spirometry  after administration of short -acting bronchodilator ( e.g., 
albuterol ). 
10. For sites with capability to collect nasal epitheli al cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
11. Record any AEs rela ted to study procedures.  
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 47 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9.3 Part B CORE  Study Only  
Subjects who are prescribed lumacaftor/ivacaftor during Part A of the study should  
complete at minimum Visits  1 and 2 before enroll ing in Part B.  
9.3.1 Visit 4 ( Pre-Dose: Day -30 to Day -1) 
Subjects who are pres cribed lumacaftor/ivacaftor will complete  Visit 4 before taking 
lumacaftor /ivacaftor. Visit 4 may occur up to 30 days prior to the planned start of 
lumacaftor /ivacaftor  (i.e., Day 1) . 
1. Review the study with the subject (subject’s legal representative) and o btain written 
informed consent and HIPAA authorization and assent, if appropriate.  (Consent may 
be obtained prior to Visit 4 .) 
2. If not a subject in Part A : 
 Assign the subject a unique subject number  
 Record demographics data and CFF Registry ID  
 Record CF dia gnosis date and genotype  
3. Measure and record height and weight.  
4. Perform clinical status review.  
5. Record menstrual cycle timing (if female of child -bearing potential)  
6. Record limited concomitant medications.  
7. Review eligibility criteria to confirm eligibility . 
8. Obtain Macroduct sweat sample.  
9. Collect blood for:  
 clinical laboratory tests (hematology)  
 banking  
10. Collect urine for banking.  
11. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
12. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a prev ious visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ) 
13. Record any AEs related to study procedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 48 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  14. Remind the subject that lumacaftor /ivacaft or should be started within 30 days after 
Visit 4 . 
15. Remind subject to notify the research coordinator of the date of the first dose of 
lumacaftor/ivacaftor in order to schedule subject for Visit 5.  
16. Schedule next visit.  
9.3.2 Visit 5  [30 Days post Day 1 ( ±7 Days) ] 
1. Measure and record h eight and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for : 
 clinical laboratory tests  (hematology)  
 banking  
7. Collect urine for banking.  
8. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to  perform induction, collect 
expectorated sputum if possible)  
9. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit spec ific procedure  that should be performed only once and at whichever 
visit is most convenient ) 
10. Record any AEs related to study procedures.  
11. Schedule next visit . 
9.3.3 Visit 6 [3 Months post Day 1 (90 Days ±30 Days)]  
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 49 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   clinical laboratory tests (hematology)  
 banking  
7. Collect urine for banking.  
8. Perform spirometry  after administration of short -acting bronchodilator ( e.g., 
albuterol) .  
9. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note : this is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ) 
10. Record any AEs related to study procedures.  
11. Schedule next visit . 
9.3.4 Visit 7 [6 Months  post Day 1  (180 Days ±30 Days)]  
1. Measure and record heig ht and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for : 
 clinical laboratory tests (hematology)  
 banking  
7. Collect urine for banking.  
8. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, colle ct 
expectorated sputum if possible)  
9. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that shoul d be performed only once and at whichever 
visit is most convenient ) 
10. Record any AEs related to study procedures.  
11. Schedule next visit . 
9.3.5 Visit 8 [12 Months  post Day 1 ( 360 Days ±30 Days)]   
1. Measure and record height and weight.  
2. Perform clinical status review.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 50 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for : 
 clinical laboratory tests (hematology)  
 banking  
7. Collect urine for banking.  
8. Perform spirometry  and s putum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
9. For sites w ith capability to collect nasal epithelial cells:  If not collected at a previous 
visit, obtain nasal epithelial cells (if DNA consent is obtained).  
10. Record any AEs related to study procedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 51 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9.4  Part B CORE  Study plus MBW/FENO  
9.4.1 Visit 4 (Pre-Dose: Day -30 to Day -1) 
Subjects who are prescribed  lumacaftor/ivacaftor will complete Visit 4 before taking 
lumacaftor/ivacaftor.  Visit 4 may occur up to 30 days prior to the planned start of 
lumacaftor/ivacaftor (i.e., Day 1).  
1. Review the study with the subject (subje ct’s legal representative) and obtain written 
informed consent and HIPAA authorization and assent, if appropriate . (Consent may 
be obtained prior to Visit 4).  
2. If not a subject  in Part A : 
 Assign the subject a unique subject number.  
 Record demographics data and CFF Registry ID  
 Record CF d iagnosis date and genotype.  
3. Measure and record height and weight.  
4. Perform clinical status review.  
5. Record menstrual cycle timing (if female of child -bearing potential)  
6. Record limited concomitant medications.  
7. Review eligibilit y criteria to confirm eligibility  for Part B CORE and MBW/FENO . 
8. Obtain Macroduct sweat sample.  
9. Collect blood for :  
 clinical laboratory tests (hematology)  
 banking  
10. Collect urine for banking.  
11. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
12. Perform FENO procedure.  
13. Perform MBW procedure . 
14. Perform spirometry and sputum induction, according to the study sequence outlined 
below : 
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum indu ction (or, if unable to perform induction, collect 
expectorated sputum if possible) as per Protocol Section 8.3.2.  
15. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA c onsent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ) 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 52 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  16. Record any AEs related to study procedures.  
17. Remind the subject that lumacaftor /ivacaftor should be started wit hin 30 days after 
Visit 4 . 
18. Remind subject to notify the research coordinator of the date of the first dose of 
lumacaftor /ivacaftor in order  to schedule subject for Visit 5.  
9.4.2 Visit 5 (Day 30 ±7 Days ) 
1. Measure and record height and weight.  
2. Perform clinical sta tus review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for :  
 clinical laboratory tests (hematology)  
 banking  
7. Collect urine for banking.  
8. Confirm t hat subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
9. Perform FENO procedure.   
10. Perform MBW procedure.  
11. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilato r (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible) as per Protocol Section 8.3.2.  
12. For sites with capability to collect nasal epithelial cells: obtain nasal epitheli al cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
13. Record any AEs related to study procedures.  
14. Schedu le next visit . 
9.4.3 Visit 6 [3 Months post Day 1 (90 Days ±30 Days) ] 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 53 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  4. Record limited concomitant medications.  
5. Obtain Macrod uct sweat sample.  
6. Collect blood for :  
 clinical laboratory tests (hematology)  
 banking  
7. Collect urine for banking.  
8. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
9. Perform MBW procedure.  
10. Perform spirometry  after admin istrating short -acting bronchodilator ( e.g., albuterol) .  
11. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific  procedure  that should be performed only once and at whichever 
visit is most convenient ). 
12. Record any AEs related to study procedures.  
13. Schedule next visit . 
9.4.4 Visit 7 [ 6 Months  post Day 1 ( 180 Days ±30 Days)]   
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for :  
 clinical laboratory tests (hematology)  
 banking  
7. Collect urine for banking.  
8. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
9. Perform FENO procedure.  
10. Perform MBW procedure.  
11. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting broncho dilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 54 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  12. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collecte d at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
13. Record any AEs related to study procedures.  
14. Schedule next visit . 
9.4.5 Visit 8 [ 12 Months  post Day 1 ( 360 Days ±30 Days)]   
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood  for:  
 clinical laboratory tests (hematology ) 
 banking  
7. Collect urine for banking.  
8. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
9. Perform MBW procedure.  
10. Perform spirometr y and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
11. For sites with capability to collect n asal epithelial cells:  If not collected previously , 
obtain nasal epithelial cells (if DNA consent is obtained).  
12. Record any AEs related to study procedures.  
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 55 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9.5 Part B CORE  Study plus MBW/FENO with  MCC  
9.5.1 Visit 4 (Pre -Dose: Day -30 to Day -1) 
Subjects who are p rescribed  lumacaftor/ivacaftor will complete Visit 4 (including the 24 
hour MCC scan) before taking lumacaftor/ivacaftor.  Visit 4 may occur up to 30 days prior 
to the planned start of lumacaftor/ivacaftor (i.e., Day 1).  
Visit 4A ( Pre-Visit )  
1. Review the st udy with the subject (subject’s legal representative) and obtain written 
informed consent and HIPAA authorization and assent, if appropriate.  Because there 
are requirements to hold certain medications prior to performing the MCC procedure, 
consent for the study will need to occur prior to Visit 4.  
2. Review eligibility criteria to confirm eligibility for CORE study and the additional 
eligibility requirements for the MBW/FENO and MCC Sub -studies before 
proceeding.  
3. Remind the subject to discontinue hypertonic sa line and rhDNase ( Pulmozyme) for at 
least 12 hours prior to Visit 4.  
 
Day of Visit:  
1. If not a subject in Part A : 
 Assign the subject a unique subject number.  
 Record demographics data and CFF Registry ID  
 Record CF diagnosis date and genotype.  
2. Measure and reco rd height and weight.  
3. Perform clinical status review.  
4. Record menstrual cycle timing (if female of child -bearing potential)  
5. Record limited concomitant medications.  
6. Review eligibility criteria to confirm eligibility  for Part B CORE and MBW/FENO . 
7. Review and confirm subject meets the additional MCC Sub -Study eligibility criteria 
before proceeding.  If the subject does not meet eligibility for participation in the 
MCC Sub -Study, only proceed with the CORE  Study and MBW/FENO sub -study 
visits and procedures (as n oted in Section 9.4) . 
8. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
9. Obtain Macroduct sweat sample.  
10. Collect blood for: 
 clinical laboratory tests (hematology )  
 banking  
11. Collect urine for : 
 pregnancy test (if female of child -bearing potential)   
 banking  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 56 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  12. Perform FENO procedure.  
13. Perform the MBW procedure.  
14. Perform background and transmission scans prior to the MCC procedure.  
15. Administer short -acting bronchodilator ( e.g., albuterol) . 
16. Perform spirometry (15 ±5 minutes after short -acting bronchodilator ) and confirm that 
the subject’s FEV1% predicted is ≥30%  before proceeding with the MCC procedure . 
17. Isotope inhalation (isotope inhalation to start 60 minutes ±15 minutes after short -
acting bronchodilator ). 
18. Perform MCC measurement  (timing of MCC measurement post short -acting 
bronchodilator needs to stay consistent at each visit for each subject ). 
19. Record any AEs related to study procedures.  
20. Remind the subject that lumacaftor /ivacaftor cannot be started until after the follow up 
scan (but within 30 days of Visit 4).  
21. Remind subject to continue withholding hypertonic saline and rhDNase (Pulmozyme) 
until completion of the 24 hour follow -up scan at Visits 4B.  
22. Have the subject return the following day (24 hours ±6 hours after the start of the 
MCC scan) . 
9.5.2 Visit 4B  (24 ±6 Hours  post Visit 4)  
1. Perform the follow -up MCC scan.  
2. Perform sputum induction (or, if unable to perform induction, collect expectorated 
sputum if possible)  
3. For sites with capability to collect nasal epithelial cells: obtain n asal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
4. Record any AEs related to study proce dures.  
5. Remind subject to notify the research coordinator of the date of the first dose of 
lumacaftor/ ivacaftor in order to schedule subject for Visit 5.  
9.5.3 Visit 5 ( Post Dose: 30 Days ±7 Days ) 
Pre-visit Reminder Call ( 1-3 days  prior to visit):  
 Date/time of v isit 
 Discontinue h ypertonic saline and rhDNase (Pulmozyme) for at least 12 hours prior 
to visit 
Day of Visit:  
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 57 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample  
6. Collect blood for: 
 clinical laboratory tests (hematology )  
 banking  
7. Collect urine for : 
 pregnancy test (if female of child -bearing potential)  
 banking   
8. Confirm subject meets the additional requi rements to conduct the MCC procedure  
(i.e., Visit 5 pregnancy test is negative , subject  has held the required medications, and 
has not required antibiotics or corticosteroids for acute lower respiratory tract 
symptoms in the last 2 weeks) .  If the subject does not meet the requirements to 
conduct t he MCC scan only proceed with the CORE  Study and MBW/FENO sub -
study procedures  for Visit 5 (Section 9.4 .2).  
9. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
10. Perform FENO procedure.  
11. Perform the MBW procedure . 
12. Perform background and transmission scans prior to the MCC procedure.  
13. Administer short -acting bronchodilator ( e.g., albuterol) . 
14. Perform spirometry (15 ±5 minutes after short -acting bronchodilator and confirm that 
the subject’s FEV1% predicted is ≥30%  before performing the MCC procedure .  
15. Isotope inhalation (isotope inhalation to start 60 minutes ±15 minutes after short -
acting bronchodilator ).  
16. Perform MCC measurement (timing of MCC measurement post short -acting 
bronchod ilator needs to stay consistent at each visit for each subject ). 
17. Record any AEs related to study procedures.  
18. Remind subject to continue withholding hypertonic saline and rhDNase (Pulmozyme) 
until completion of the 24 hour follow -up scan at Visits 5 B. 
19. Have the subject return the following day (24 hours ±6 hours after the start of the 
MCC scan).  
9.5.4 Visit 5B  (24 ±6 Hours Post Visit 5 ) 
1. Perform the follow -up MCC scan.  
2. Perform sputum induction (or, if unable to perform induction, collect expectorated 
sputum if possi ble)  
3. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 58 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  non-visit specific procedure  that should be performed only once and at  whichever 
visit is most convenient ). 
4. Record any AEs related to study procedures.  
5. Schedule next visit.  
9.5.5 Visit 6 [3 Months post Day 1 (90 Days ±30 Days) ] 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential) . 
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for: 
 clinical laboratory tests (hematology )  
 banking  
7. Collect urine for banking.   
8. Confirm that subject did not have any carbonated drink s 30 minutes prior to MBW 
procedure.  
9. Perform MBW procedure.  
10. Perform spirometry  after administration of short -acting bronchodilator ( e.g., 
albuterol).  
11. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collecte d at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
12. Record any AEs related to study procedures.  
13. Schedule  next visit.  
9.5.6 Visit 7 [ 6 Months  post Day 1 ( 180 Days ±30 Days)]   
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for: 
 clinical laboratory tests (hematology )  
 banking  
7. Collect urine for banking.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 59 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  8. Confirm that subject did not have any carbonated drinks 30 minutes prior to MBW 
procedure.  
9. Perform FENO procedure.  
10. Perform MBW procedure.  
11. Perform spirometry and sput um induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
12. For sites wit h capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is  most convenient ). 
13. Record any AEs related to study procedures.  
14. Schedule next visit.  
9.5.7 Visit 8 [ 12 Months  post Day 1 ( 360 Days ±30 Days)]   
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Obtain Macroduct sweat sample.  
6. Collect blood for: 
 clinical laboratory tests (hematology )  
 banking  
7. Collect urine for banking.  
8. Confirm that subject did not have any carbonated drinks 30 minutes prior  to MBW 
procedure . 
9. Perform MBW procedure.  
13. Perform spirometry  and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perfor m induction, collect 
expectorated sputum if possible).  
10. For sites with capability to collect nasal epithelial cells:  If not collected previously , 
obtain nasal epithelial cells (if DNA consent is obtained).  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 60 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  11. Record any AEs related to study procedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 61 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9.6 Part  B CORE  Study plus GIFT  
9.6.1 Visit 4 (Pre Dose: Day -30 to Day -1) 
Subjects who are prescribed  lumacaftor /ivacaftor will complete  Visit 4 before taking 
lumacaftor /ivacaftor.  Visit 4 may occur up to  30 days  prior to the planned start of 
lumacaftor /ivacaftor  (i.e., Day 1) . 
Visit 4A ( Pre-Visit )  
1. Review the study with the subject (subject’s legal representative) and obtain written 
informed consent and HIPAA authorization and assent, if appropriate.  Because there 
are requirements to hold certain medications prior t o performing the GIFT procedures, 
consent for the study will need to occur prior to Visit 4.  
2. Review eligibility criteria to confirm eligibility for CORE  study  and the additional 
eligibility requirements for the GIFT Sub -study before proceeding.  
3. If subject  receives insulin:  
 Provide the subject with the 3 -Day Insulin Diary and instructions  to 
bring to Visit 4  
 Remind them to d iscontinue all rapid -acting insulin for at least 6 hours 
prior to Visit 4 
4. Provide the subject with the stool collection  kit and instru ctions to collect the sample 
prior to  Visit 4 , freeze  and br ing with them to Visit 4 .  
 Note: Subjects who participated in Part A and have had stool sample 
collected at Visit 2 do not need to collect stool for Visit 4. 
5. Remind the subject that n o solids or l iquids with the exception of water  and no enteric 
tube feedings are allowed for 8 hours prior to Visit 4.  
Visit 4  
1. Re-confirm eligibility for CORE  study  and the additional eligibility requirements for 
the GIFT Sub -study before proceeding. If the subject do es not meet the additional 
eligibility requirements for the GIFT Sub -study, proceed with the CORE Study visits 
and procedures only (as noted in Section 9.3) . 
2. If not a subject in Part A : 
 Assign the subject a unique subject number  
 Record demographics data an d CFF Registry ID  
 Record CF diagnosis date and genotype  
3. Obtain the stool sample from the subject  
4. Measure and record height and weight.  
5. Perform clinical status review.  
6. Record menstrual cycle timing (if female of child -bearing potential)  
7. Record limited concomitant medications.  
8. Collect 3 -Day Insulin Diary or r ecord insulin daily dose per recal l (if applicable) . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 62 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9. Obtain Macroduct sweat sample.  
10. Collect urine for banking.  
11. Place a saline trap or heparin lock for blood draws.  
12. Collect blood (within 15 minutes prior  to GlucoCrush ingestion) for: 
 clinical laboratory tests (hematology )  
 HbA1c   
 banking   
 baseline OGTT ( glucose, insulin and c -peptide levels )  
13. Collect baseline breath sample (within 1 5 minutes prior to GlucoCrush ingestion ). 
14. Have the subject drink 1.75 gm/k g (maximum  75 grams) of glucose (GlucoCrush) . 
15. Perform b reath tests at the following time points after  completion of GlucoCrush  
ingestion :  
 15 minutes  
 30 minutes  
 45 minutes  
 60 minutes  
 90 minutes  
 120 minutes  
16. Collect blood for OGTT at the following time point s after completion of GlucoCrush 
ingestion : 
 30 minutes  
 60 minutes  
 90 minutes  
 120 minutes   
17. Within 15 minutes after the 120 minute blood draw and breath testing, provide the 
subject with at least 30 grams carbohydrate.  
18. Perform spirometry and sputum inductio n, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
19. For sites with capability  to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most conven ient). 
20. Record any AEs related to study procedures.  
21. Provide su bject with 3-Day Insulin Diary  (if applicable) .  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 63 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  22. Remind the subject that lumacaftor /ivacaftor should be started within 30 days after 
Visit 4.  
23. Remind the subject to notify the research coordinator  of the date of the first dose of 
lumacaftor /ivacaftor in order to schedule the subject to return for Visit  5. 
9.6.2 Visit 5  (30 Days post Day  1 ±7 Days)   
Pre-visit Reminder  Call (at least 3 days prior to Visit) : 
 Date/time of Visit  
 Insulin use (if applicable)  
o Complete 3-Day Insulin Diary 
o Hold rapid -acting  insulin for at least 6 hours prior to visit  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hours prior to visit   
Day of V isit: 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Collect 3 -Day Insulin Diary or record insulin daily dose per recall (if applicable) .  
6. Obtain Macroduct sweat sampl e. 
7. Collect urine for banking.  
8. Place a saline trap or heparin lock for blood draws.  
9. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
 clinical laboratory tests (hematology )  
 banking  
 baseline OGTT ( glucose, insulin and c -peptide levels )  
10. Collect baseline breath sample (within 1 5 minutes prior to GlucoCrush ingestion) .  
11. Have the subject drink 1.75 gm/kg (maximum 75  grams) of glucose (GlucoCrush).  
12. Perform b reath tests at the following time points after completion of GlucoCrush 
ingestion :  
 15 minutes  
 30 minutes  
 45 minutes  
 60 minutes  
 90 minutes  
 120 minutes  
13.  Collect blood for OGTT  at the following time points after completion of GlucoCrush 
ingestion : 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 64 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   30 minutes  
 60 minutes  
 90 minutes  
 120 minutes   
14. Within 15 minutes after the 120 minute blood draw  and breath testing, provide the 
subject with at least 30 grams carbohydrate.  
15. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry  
 Perform sputu m induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
16. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
17. Record any AEs related to study procedures.  
18. Provide the subject with stool collection instructions and supplies.  
19. Schedule next visit.  
9.6.3 Visit 6 [3 Months post Day 1 (90 Days ±30 Days) ] 
Pre-visit Reminder  Call (at least 3 days prior to Visit) : 
 Date/time of v isit 
 Collect, freeze and bring stool sample to visit.  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hours prior to visit   
Day of Visit:  
1. Obtain subject -collected stool sample (frozen) . 
2. Measure and record height and weight.  
3. Perform clinical status review .  
4. Record menstrual cycle timing (if female of child -bearing potential)  
5. Record limited conc omitant medications . 
6. Obtain Macroduct sweat sample.  
7. Collect blood for :  
 clinical laboratory tests (hematology )  
 banking  
8. Collect urine for banking.  
9. Perform spirometry  after administration of short -acting bronchodilator ( e.g., albuterol) . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 65 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  10. For sites with capa bility to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a non -
visit specific procedure  that should be performed only once and at whichever visit is 
most convenient ). 
11. Provide the subject with 3-Day Insulin Diary  (if subject receives insulin) . 
12. Record any AEs related to study procedures.  
13. Schedule next visit . 
9.6.4 Visit 7  [6 Months post Day 1  (180 Days  ±30 Days) ]  
Pre-visit Reminder  Call (at least 3 days prior to v isit): 
 Date/time of Visit  
 Insulin use (if applicable)  
o Complete 3 -Day Insulin Diary 
o Hold rapid -acting  insulin for at least 6 hours prior to visit  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at 
least 8 hours prior to vis it  
Day of V isit: 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Collect 3 -Day Insulin Diary or record insulin daily dose pe r recall (if applicable) . 
6. Obtain Macroduct Sweat Sample  
7. Collect urine for banking.  
8. Place a saline trap or heparin lock for blood draws.  
9. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
 clinical laboratory tests (hematology )  
 HbA1c   
 bank ing  
 baseline OGTT ( glucose, insulin and c -peptide levels ) 
10. Have the subject drink 1.75 gm/kg (maximum 75  grams) of glucose (GlucoCrush).  
11. Collect blood for OGTT  at the  following time points after completion of GlucoCrush 
ingestion :  
 30 minutes  
 60 minutes  
 90 minutes  
 120 minutes   
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 66 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  12. Within 15 minutes after the 120 minute blood draw, provide the subject with at least 
30 grams carbohydrate.  
13. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilat or (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
14. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a  previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
15. Record any AEs related to study procedures.  
16. Provide the subject with 3 -Day Insul in Diary (if subject receives insulin) .  
17. Schedule next visit.  
9.6.5 Visit 8  [12 Months  post Day 1 (360 Days ±30 Days) ]  
Pre-visit Reminder  Call (at least 3 days prior to Visit) : 
 Date/time of Visit  
 Insulin use (if applicable)  
o Complete 3-Day Insulin Diary 
o Hold rapid-acting  insulin for at least 6 hours prior to visit  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hours prior to visit   
Day of V isit: 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Reco rd menstrual cycle timing (if female of child -bearing potential)  
4. Record limited concomitant medications.  
5. Collect 3 -Day Insulin Diary or record insulin daily dose per recall (if applicable) . 
6. Obtain Macroduct sweat sample.  
7. Collect urine for banking.  
8. Place a saline trap or heparin lock for blood draws.  
9. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
 clinical laboratory tests (hematology )  
  HbA1c   
 banking  
 baseline OGTT ( glucose, insulin and c -peptide levels )  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 67 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  10. Have the subject drink 1.75 gm /kg (maximum 75  grams) of glucose (GlucoCrush).  
11. Collect blood for OGTT  at the following time points after completion of GlucoCrush 
ingestion :  
 30 minutes  
 60 minutes  
 90 minutes  
 120 minutes   
12. Within 15 minutes after the 120 minute blood draw, provide the sub ject with at least 
30 grams carbohydrate.  
14. Perform spirometry  and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perfor m induction, collect 
expectorated sputum if possible).  
13. For sites with capability to collect nasal epithelial cells :  If not collected at a previous 
study visit, obtain nasal epithelial cells  (if DNA consent is obtained).  
14. Record any AEs related to study pr ocedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 68 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9.7 Part B CORE  Study plus GIFT  with pH Pill   
9.7.1 Visit 4 (Pre -Dose: Day -30 to Day -1)  
Subjects who are prescribed  lumacaftor/ivacaftor will complete  Visit 4 and have passed the 
pH pill before taking luma caftor/ivacaftor.  Visit 4 may occur up to 30 d ays prior to the 
planned start of lumacaftor /ivacaftor  (i.e., Day 1) . 
Visit 4A ( Pre-Visit )  
4. Review the study with the subject (subject’s legal representative) and obtain written 
informed consent and HIPAA authorization and assent, if appropriate.  Because t here 
are requirements to hold certain medications prior to performing the GIFT and pH pill 
procedures, consent for the study will need to occur prior to Visit 4.  
5. Review eligibility criteria to confirm eligibility for CORE  study  and the additional 
eligibili ty requirements for the GIFT and pH pill Sub -study before proceeding.  
6. If subject receives insulin:  
 Provide the subject with the 3 -Day Insulin Diary and instructions  to 
bring to Visit 4  
 Remind them to d iscontinue all rapid -acting insulin for at least 6 hours 
prior to Visit 4 
7. Provide the subject with the stool collection kit  and instructions to collect the sample 
prior to  Visit 4 and br ing with them to Visit 4 .  
Note: Subjects who participated in Part A and have had stool sample 
collected at Visit 2 do not need to collect stool for Visit 4. 
8. Remind  the subject of the following additional study requirements:   
 Discontinue p roton pump inhibitors for one week prior to Visit 4  
 Discontinue histamine -2 blockers and narcotic medications for two days prior to 
Visit 4.  
 Discontinue calcium, magnesium or aluminum antacids for one day prior to Visit 
4. 
 Abstain from alcohol for 24 hours  prior to Visit 4 . 
 No solids or liquids with the exception of water  and no enteric tube  feedings for 
at least 8 hours prior to visit.  
NOTE : Subjects participating in pH Pill sub -study should not have any liquids 
2 hours prior to the procedure and a total amount of water consumed during 
the fasting period should not exceed 6 oz of water.   
Day of Visit : 
1. Re-confirm eligibility for CORE  study  and the additional eligibility requirements for 
the GIFT Sub -study before proceeding. If the subject does not meet the additional 
eligibility requirements for the GIFT Sub -study, proceed with the CORE Study visits 
and procedures only (as noted in Section 9.3 ). 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 69 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  2. If not a subject in Part A:  
 Assign the subject a unique subject number  
 Record demographics data and CFF Registry ID  
 Record CF diagnosis date and genotype  
3. Obtain the stool sample from the subject  
4. Measure and record height and weight.  
5. Perform clinical st atus review . 
6. Record menstrual cycle timing (if female of child -bearing potential)  
7. Record limited concomitant medications .  
8. Collect 3 -day insulin diary or r ecord insulin daily dose per recall  (if applicable) . 
9. Review eligibility criteria to confirm eligibili ty for CORE  study.  
10. Obtain Macroduct sweat sample.  
11. Collect urine for : 
 pregnancy testing  (if female of child -bearing potential) . 
 banking  
12. Perform GI symptom assessment.  
13. Perform abdominal physical exam.  
14. Confirm subject meets the additional pH Pill Sub -Study V isit 4 eligibility criteria 
before proceeding.   
 If the subject does not meet the eligibility for participation in the pH Pill 
Sub-Study  and meets the eligibility criteria for GIFT , proceed with the 
CORE  Study plus GIFT visits and procedures only  (Section 9.6). 
15. Have subject complete the modified symptom sub -scale  of the CFQR.  
16. Place a saline trap or heparin lock for blood draws.  
17. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
 clinical laboratory tests (hematology )  
 HbA1c   
 banking  
 baseli ne OGTT ( glucose, insulin and c -peptide levels )  
18. Collect baseline breath sample (within 1 5 minutes prior to GlucoCrush ingestion).  
19. Turn on the radiofrequency detector, and then turn on the pH pill with the magnet.  
Record the pH Pill number in the source do cuments.  (Reminder: once activated, the 
radiofrequency detector needs to remain within 3 feet of the subject at all times.)   
20. Have the subject drink 1.75 gm/kg (maximum  75 grams) of glucose (GlucoCrush) . 
21. Subjects should swallow their pH pill with the GlucoC rush.  Record the date and time  
that the pH pill was  swallowed in the source documents.  
22. Perform b reath tests at the following time points after completion of GlucoCrush 
ingestion : 
 15 minutes  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 70 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   30 minutes  
 45 minutes  
 60 minutes  
 90 minutes  
 120 minutes  
23. Collect b lood for OGTT  at the  following time points after completion of GlucoCrush 
ingestion : 
 30 minutes  
 60 minutes  
 90 minutes  
 120 minutes   
24. Within 15 minutes after the 120 minute blood draw and breath testing, provide the 
subject with at least 30 grams carbohydrat e.  
25. Perform spirometry and sputum induction, according to the study sequence outlined 
below . 
 Administer short -acting bronchodilator ( e.g., albuterol)  
 Perform spirometry (15 ±5 minutes after short -acting bronchodilator ). 
 Perform sputum induction (or, if una ble to perform induction, collect 
expectorated sputum if possible)  
26. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ).. 
27. Record any AEs related to study procedures . 
28. Provide subject with 3-Day Insulin  Diary  (if subject receives insulin) .  
29. Provide the subject with instructions on the use of the radiofrequency  detector  (and 
review with them) . 
30. Provide the subject with the pre -paid mailer and instruct the subject to send the 
radiofrequency detector and the return form  to Buffalo  in the pre -paid mailer as noted 
in the instructions.  
31. Remind the subject that you will be calling them within 24 hours .  
32. If applicable, remind subject to hold any enteric tube feedings until after the pH pill 
has passed.  
33. Remind the subject that lumacaftor /ivacaftor should be started within 30 days after 
Visit  4 (but not before the pH pill is passed).  
34. Remind the subject to notify the research coordinator of the date of the first dose of 
lumacaftor /ivacaftor in order  to schedule the subject to return for Visit  5. 
Call 4B (Visit 4 + 1Day ) 
One ( 1) day after the in gestion of the pH Pill  
1. Confirm that the subject is using the device . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 71 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  2. Assess if any adverse events have occurred.  
3. Assess if the subject has passed the pH pill.  (The radiofrequency detector will display 
an “X” ). 
4. Remind the subject to return the radiofrequen cy detector and the return form  to Buffalo 
as per the instructions . 
9.7.2 Visit 5 (Day 30 ±14 Days)   
Pre-visit Reminder Call ( at least one week prior to Visit) :  
 Date/time of visit  
 Discontinue p roton pump inhibitors for one week prior to visit. 
 Discontinue hista mine -2 blockers and narcotic medications for two days prior to visit.  
 Discontinue calcium, magnesium or aluminum antacids for one day prior to visit.  
 Abstain from alcohol for 24 hours . 
 Insulin use (if applicable)  
o Complete 3-Day Insulin Diary 
o Hold all rapid-acting  insulin for at least 6 hours prior to visit  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hours prior to visit . 
 NOTE: Subjects participating in pH Pill sub -study should not have any liquids 2 
hours p rior to the procedure and a total amount of water consumed during the fasting 
period should not exceed 6 oz of water.    
Day of Visit : 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential) . 
4. Record limited concomitant medications.  
5. Collect 3 -Day Insulin Diary or record insulin daily dose per recall (if applicable) . 
6. Obtain Macroduct sweat sample.  
7. Collect urine for: 
 pregnancy testing  (females of child -bearing potential) . 
 banking  
8. Perform GI symptom assessment.  
9. Perform abdominal physical exam.  
10. Confirm subject meets criteria to perform the pH pill test  (subject has withheld all 
required medications, is not pregnant, and has not had l oose watery stools within the 
last two weeks more than three times a day lasting more than 24 hours, or has not been  
vomiting within the two weeks prior to the visit).  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 72 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  11. Have subject complete the modified symptom sub -scale  of the CFQR.  
12. Place a saline trap or heparin lock for blood draws.  
13. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
 clinical laboratory tests (hematology )  
 banking  
 baseline OGTT ( glucose, insulin and c -peptide levels )  
14. Collect baseline breath sample (within 1 5 minutes  prior to GlucoCrush ingestion) . 
15. Turn on the radiofr equenc y detector, and then turn on the pH pill with the magnet.    
Record the pH pill number in the source documents. (Reminder: once activated, the 
radiofrequency detector needs to remain within 3 feet of the subject at all times.)    
16. Have the subject drink  1.75 gm/kg (maximum 75 grams) of glucose (GlucoCrush) . 
17. Subjects should swallow their pH pill with the GlucoCrush.   Record the date and time  
that the pH pill was  swallowed in the source documents.  
18. Perform b reath tests at the following time points after completion of GlucoCrush 
ingestion : 
 15 minutes  
 30 minutes  
 45 minutes  
 60 minutes  
 90 minutes  
 120 minutes  
19. Collect blood for OGTT at the following  time points after completion of GlucoCrush 
ingestion :  
 30 minutes  
 60 minutes  
 90 minutes  
 120 minutes   
20. Within 15 minu tes after the 120 minute blood draw and breath testing, provide the 
subject with at least 30 grams carbohydrate.  
21. Perform spirometry and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator ( e.g., albutero l) 
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible)  
22. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (a nd if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever visit 
is most convenient ). 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 73 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  23. Record any AEs related to study procedures.  
24. Provide the subjects with instructions on the use of t he radiofrequency  detector  (and 
review with them) . 
25. Provide the subject with the pre -paid mailer and instruct the subject to send the 
radiofrequency detector and the return form  to Buffalo  in the pre -paid mailer as noted 
in the instructions.  
26. If applicable, remind subject to hold any enteric tube feedings until after the pH pill 
has passed.  
27. Remind the subject that you will be calling them within 24 hours .  
28. Provide the subject with stool collection instructions and supplies.  
29. Schedule next visit.  
 
Call 5B (Visi t 5 + 1  Day)  
One ( 1) day after the ingestion of the pH Pill  
1. Confirm that the subject is using the device . 
2. Assess if any adverse events have occurred.  
3. Assess if the subject has passed the pH Pill.  (The radiofrequency detector will display 
an “X” ). 
4. Remind t he subject to return the radiofrequency detector and the return form  to 
Buffalo as per the instructions.  
9.7.3 Visit 6 [3 Months post Day 1 (90 Days ±30 Days) ] 
Pre-visit Reminder  Call (at least 1 week  prior to Visit):  
 Date/time of visit  
 Collect, freeze and bring  stool sample to visit.  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hours prior to visit   
Day of Visit : 
1. Obtain subject -collected stool sample (frozen)  
2. Measure and record height and weight.  
3. Perform clinical s tatus review.  
4. Record menstrual cycle timing (if female of child -bearing potential)  
5. Record limited concomitant medications.  
6. Obtain Macroduct sweat sample.  
7. Collect blood for  
 clinical laboratory tests (hematology )  
 banking  
8. Collect urine for banking . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 74 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  9. Perform spirometry  after administration of short -acting bronchodilator ( e.g., 
albuterol).  
10. For sites with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever visit 
is most convenient ). 
11. Record any AEs related to study procedures.  
12. Provide the subject with 3 -Day Insulin Diary (if subject receives insulin) .  
13. Schedule next visit.  
9.7.4 Visit 7 [6 Months post Day 1 (180 Days ±30 Days) ]  
Pre-visit Reminder  Call (at least 3 days prior to visit) : 
 Date/time of Visit  
 Insulin use (if applicable)  
o Complete 3-Day Insulin Diary 
o Hold rapid -acting  insulin for at least 6 hours prior to visit  
 No solids  or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hours prior to visit   
Day of V isit: 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potentia l) 
4. Record limited concomitant medications.  
5. Collect 3 -Day Insulin Diary or record insulin daily dose per recall (if applicable) . 
6. Obtain Macroduct sweat sample.  
7. Collect urine for banking.  
8. Place a saline trap or heparin lock for blood draws.  
9. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
  clinical laboratory tests (hematology )  
 HbA1c   
 banking  
 baseline OGTT ( glucose, insulin and c -peptide levels )  
10. Have the subject drink 1.75 gm/kg (maximum75 grams) of glucose (GlucoCrush).  
11. Collect blood f or OGTT at the  following time points after completion of GlucoCrush  
ingestion:  
 30 minutes  
 60 minutes  
 90 minutes  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 75 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   120 minutes   
12. Within 15 minutes after the 120 minute blood draw , provide the subject with at least 
30 grams carbohydrate.  
13. Perform spirometry  and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible).  
 
14. For si tes with capability to collect nasal epithelial cells: obtain nasal epithelial cells if 
not collected at a previous visit (and if DNA consent was obtained ). (Note: t his is a 
non-visit specific procedure  that should be performed only once and at whichever 
visit is most convenient ). 
15. Record any AEs related to study procedures.  
16. Provide the subject with 3 -Day Insulin Diary (if subject receives insulin) .  
17. Schedule next visit.  
9.7.5 Visit 8 [12 Months post Day 1 (360 Days ±30 Days) ]  
Pre-visit Reminder  Call (at least 3 days prior to Visit) : 
 Date/time of Visit  
 Insulin use (if applicable)  
o Complete 3-Day Insulin Diary 
o Hold rapid -acting  insulin for at least 6 hours prior to visit  
 No solids or liquids with the exception of water  and no enteric tube  feedings for at least 
8 hou rs prior to visit . 
Day of V isit: 
1. Measure and record height and weight.  
2. Perform clinical status review.  
3. Record menstrual cycle timing (if female of child -bearing potential) . 
4. Record limited concomitant medications.  
5. Collect 3 -Day Insulin Diary or record insul in daily dose per recall (if applicable) . 
6. Obtain Macroduct sweat sample.  
7. Collect urine for banking.  
8. Place a saline trap or heparin lock for blood draws.  
9. Collect blood (within 15 minutes prior to GlucoCrush ingestion) for: 
  clinical laboratory tests (hemato logy)  
 HbA1c   
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 76 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   banking  
 baseline OGTT ( glucose, insulin and c -peptide levels )  
10. Have the subject drink 1.75 gm/kg (maximum75 grams) of glucose (GlucoCrush).  
11. Collect blood for OGTT at the  following time points after completion of GlucoCrush  
ingestion:  
 30 min utes 
 60 minutes  
 90 minutes  
 120 minutes   
12. Within 15 minutes after the 120 minute blood draw , provide the subject with at least 
30 grams carbohydrate.  
15. Perform spirometry  and sputum induction, according to the study sequence outlined 
below.  
 Administer short -acting bronchodilator (e.g., albuterol)  
 Perform spirometry  
 Perform sputum induction (or, if unable to perform induction, collect 
expectorated sputum if possible).  
13. For sites with capability to collect nasal epithelial cells :  If not collected at previous  
study visit , obtain nasal epithelial cells  (if DNA consent is obtained).  
14. Record any AEs related to study procedures.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 77 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  10 ADVERSE EXPERIENCE R EPORTING AND DOCUMEN TATION  
10.1 Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a subject  that is participating 
in this clinical investigation and is a result of the research study procedures.   
The Investigator will monitor for the occurrence of study procedure -related AEs during 
each subject visit and record the information in the site’s source docum ents.  Adverse events 
will be recorded in the subject  CRF.  Adverse events will be described by duration (start and 
stop dates and times), severity, outcome, treatment and relation to study procedure.  
During this observational study,  the combination therap y lumacaftor/ ivacaftor is expected to 
be a marketed product prescribed in accordance with its approved usage.  Any adverse event 
that an investigator believes is related to lumacaftor/ ivacaftor and that is clinically 
significant should be reported directly  to the FDA via a MedWatch form.  
AE Severity  
The National Cancer Institute’s Common Terminology Criteria for Adverse Events 
(CTCAE) Version 4.0, as modified for cystic fibrosis, should be used to assess and grade 
AE severity, including laboratory abnormali ties judged to be clinically significant. The 
modified criteria can be found in the study manual.  If the experience is not covered in the 
modified criteria, the guidelines shown in Table 1  below should be used to grade severity.  
It should be pointed out that the term “severe” is a measure of intensity and that a severe AE 
is not necessarily serious.  
Table 1.  AE Severity Grading  
Severity (Toxicity Grade)  Description  
Mild (1)  Mild; asymptomatic or mild symptoms; clinical or 
diagnos tic observations only; intervention not indicated.  
Moderate (2)  Moderate; minimal, local or noninvasive intervention 
indicated; limiting age -appropriate Instrumental 
activities of daily living (e.g., preparing meals, using the 
telephone, managing money)  
Severe (3)  Severe or medically significant but not immediately life -
threatening; hospitalization or prolongation of 
hospitalization indicated; disabling; limiting self -care 
activities of daily living (e.g., bathing, dressing, feeding 
self, using toilet, ta king medications)  
Life-threatening (4)  Life-threatening consequences; urgent intervention 
indicated.  
Death (5)  Death Related to AE  
 
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 78 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  AE Relationship to Study Procedure  
The relationship of an AE to the study procedure should be assessed using the follow ing the 
guidelines in  Table 2.  
Table 2.  AE Relationship to Study Procedure  
Relationship  
to Study 
Procedure  Comment  
Definitely  An event that follows a reasonable temporal sequence from the study 
procedure: that follows a known or e xpected response pattern to the 
study procedure; and that is not explained by any other reasonable 
hypothesis.  
Probably  An event that follows a reasonable temporal sequence from the study 
procedure; that follows a known or expected response pattern to th e 
study procedure; and that is unlikely to be explained by the known 
characteristics of the subject’s clinical state or by other interventions.  
Possibly  An event that follows a reasonable temporal sequence from the study 
procedure; that follows a known or  expected response pattern to the 
study procedure; but that could readily have been produced by a 
number of other factors.  
10.2 Serious Adverse Experiences (SAE)  
An SAE is defined as any AE occurring that results in any of the following outcomes:  
 death  
 a life -threatening adverse experience  
 inpatient hospitalization or prolongation of existing hospitalization  
 a persistent or significant disability/incapacity  
 a congenital anomaly/birth defect  
Other important medical events may also be considered an SAE when, bas ed on appropriate 
medical judgment, they jeopardize the subject or require intervention to prevent one of the 
outcomes listed.  
10.2.1  Serious Adverse Experience Reporting  
Study sites will document any SAEs that are considered related to study procedures on an 
SAE Report Form.  The collection period for all SAEs will begin after informed consent is 
obtained and end after procedures for the final study visit have been completed.  
All SAE Report Forms will be reviewed by the site investigator and sent to the TDNCC 
within one business day of the site learning of the event.  Sites will fax the SAE report to:  
 
TDNCC SAE Fax: (206) 985 -3278  
Or scan and email the SAE Report to: cfsaesfacsys@seattlechildrens.org  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 79 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  The site will notify the TDNCC of additional information or fo llow-up to an initial SAE 
Report as soon as relevant information is available.  Follow -up information is reported on 
an SAE Report Form.  
In accordance with the standard operating procedures and policies of the local Institutional 
Review Board (IRB)/Indepen dent Ethics Committee (IEC), the site investigator will report 
SAEs to the IRB/IEC.   
10.3 Protocol Defined Important Medical Findings Requiring Real Time Reporting  
pH Pill Sub -Study: Specific procedures to following in the event of a retained WMC.  
If a subject  has not passed the capsule 14 days after ingestion and the pH profile as well as 
pressure profile as reviewed by the Children’s Hospital of Buffalo upon receiving the 
radiofrequency detector does not indicate that it has passed into the colon, abdominal x -rays 
(flat and upright) will be obtained.   If the capsule is identified by x -ray but the subject is not 
having pain and does not have evidence of air -fluid levels, polyethylene glycol (17 grams in 
8 ounces of liquid) will be prescribed, to be taken orally  three times a day until the capsule 
has passed into the colon or has been evacuated.   Consultation with a gastroenterologist for 
possible endoscopy and manual removal will be scheduled if the subject has severe 
abdominal pain secondary to capsule retentio n, with air -fluid level on abdominal x -rays. 
Study sites will follow the SAE reporting requirements as specified in section 10.2.1 for any 
subject experiencing capsule retention 14 days after ingestion.  
10.4 Medical Monitoring  
TDNCC Medical Monitoring Group should be contacted directly at this  number to report 
medical concerns or questions regarding safety.  
Pager: (800) 341 -0961  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 80 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  11 DISCONTINUATION AND REPLACEMENT OF  SUBJECTS  
11.1 Withdrawal of Subjects from the Study  
A subject may be withdrawn from the study at any ti me if the subject, the investigator, or 
the Sponsor feels that it is not in the subject’s best interest to continue.  Note: 
discontinuation of lumacaftor/ivacaftor does not require withdrawal from the study.   
All subjects are free to withdraw from partici pation at any time, for any reason, specified or 
unspecified, and without prejudice.      
Reasonable attempts will be made by the investigator to provide a reason for subject 
withdrawals.   The reason for the subject’s withdrawal from the study will be speci fied in the 
subject’s source documents.     
11.2 Replacement of Subjects  
Subjects who withdraw from the study can be replaced.   
12 PROTOCOL VIOLATIONS  
A protocol violation occurs when the subject, investigator, or the Sponsor fails to adhere to 
significant protoco l requirements affecting the inclusion, exclusion, subject safety and 
primary endpoint criteria.  Protocol violations for this study include, but are not limited to, 
the following:  
1. Failure to meet inclusion/ exclusion  criteria  
2. For subjects enrolled in any o f the sub -studies: Sub -study procedures performed 
when subject did not meet the listed criteria for the safe performance of the 
procedure.  
Failure to comply with Good Clinical Practice  (GCP)  guidelines will also result in a 
protocol violation.  
When a prot ocol violation occurs, it will be discussed with the investigator and a Protocol 
Violation Form detailing the violation will be generated. This form will be signed by a 
Sponsor representative and the Investigator. A copy of the form will be filed in the si te’s 
regulatory binder and in the Sponsor’s files.  The site will report the violation to their IRB in 
accordance with their IRB reporting requirements.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 81 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  13 STATISTICAL METHODS AND CONSIDERATIONS  
Prior to the analysis of the final study data, a detailed Statis tical Analysis Plan (SAP) will 
be written, describing all analyses that will be performed.  The SAP will contain any 
modifications to the analysis plan described below.   
13.1 Data Sets Analyzed  
All eligible subject s who provide informed consent will be include d in the analyses.  The 
core and sub -studies will be linked so that associations between primary and secondary 
endpoints from each sub -study and clinical parameters (e.g., spirometry, weight, or sweat 
chloride , etc. ) collected as part of the CORE  Study may  be explored in the future. Parts A 
and B will be analyzed separately ; however , visits that were performed as Part A in subject s 
who went onto Part B may be treated as baseline visits for Part B.  
No imputation will be made for missing data. As a sensitivi ty analysis, select missing data 
methods will be employed to assess the impact of missing data on the primary endpoint. For 
both the CORE STUDIES and each SUB -STUDY, all formal hypothesis testing will be 
performed at the two -sided alpha 0.05 level. All pro tocol violations will be included as a 
listing.  
13.2 Demographic and Baseline Characteristics  
Demographic and baseline variables will be summarized by cohort, part, and sub -study 
participation, including race, gender, age, CFTR genotype, height, weight, and spi rometry.  
Continuous variables will be summarized using descriptive summary statistics including: 
number of subjects (N), mean, standard deviation (SD), median, minimum and maximum. 
Categorical variables will be summarized using counts and percentages. For  categorical 
demographic characteristics, Fisher’s exact test will be used to compare cohorts (Part A 
only).  
Part A, Cohort 3 enrollment will be monitored throughout the study for genotype (F508del 
homozygous, heterozygous, and other), FEV 1 % predicted , and age distribution.  Should 
imbalance occur, sites may be encouraged to recruit under -enrolling strat a and enrollment 
may close for certain genotype -FEV 1-age criteria.  
13.3 Analysis of Primary Endpoints  
Part A CORE Study  
Sweat chloride by cohort will be summariz ed using repeated measures ANOVA, including 
means and 95% confidence intervals.  Global tests for difference between cohorts and pair -
wise tests will also be performed.  
Part A pH pill S ub-study  
Summary statistics and 95% confidence intervals will summarize  pH in the first 30 minutes 
between subjects in Cohort 2 to those in Cohort 3, and tested with a two -sample t -test. 
Part B CORE Study 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 82 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  Change in FEV 1 from Baseline to Visit 7 among those who took lumacaftor/ivacaftor  in 
Part B will be summarized and tested via paired -t test and longitudinal mixed effect 
modeling adjusted for baseline FEV 1 and age.  
Part B GIFT S ub-study  
For the glucose/insulin functional testing:  summary statistics and 95% confidence intervals 
will be summarized for changes in area under the  insulin and c -peptide curves from 
Baseline to Visit 5, and tested via the paired t -test. Estimates of mean AUCs and changes 
from Baseline at each subsequent Visit will be obtained by repeated measures ANOVA.  
For the gastro -intestinal functional testing: t he percent of subjects with negative breath test 
at Visit 5 among those positive at Baseline will be estimated with 95% CI (Wilson’s score -
based).  
Part B pH pill Sub-study  
Summary statistics and 95% confidence intervals will be presented. A paired t -test w ill be 
used to compare the change in pH (during initial 30 minutes) from Baseline to Visit 5.  
Part B MBW/FENO Sub-study  
For MBW: Summary statistics and 95% confidence intervals will be presented for change in 
LCI. A paired t -test will be performed to compa re Visit 7 LCI measurements to baseline. 
Changes in LCI across all time points will be assessed by generalized estimating equations. 
Feasibility will be assessed as the percentage of subjects producing research quality 
measurements for the primary study en dpoint (both baseline and Visit 7) and at each time 
point.  
For FENO: Summary statistics and 95% confidence intervals will be presented for  change 
in FENO.  A paired t -test will be performed to compare Visit 5 measurements to baseline. 
Changes in FENO acr oss all time points will be assessed by generalized estimating 
equations.  
Part B MCC Sub-study  
Summary statistics and 95% confidence intervals will summarize change in average whole 
lung clearance from Baseline to Visit 5, and tested with a paired t -test. 
13.4 Analysis of Secondary Endpoints  
Comprehensive details of secondary endpoints will be outlined in the SAP. The following 
considerations will guide development of these secondary endpoints:  
1. For Part A, the mean response for each cohort incorporating data fro m all visits will be 
compared using repeated measures ANOVA test. For part B, Generalized Estimating 
Equations (GEE) models will allow estimation of the change over time in the response 
variable. Potential confounders that affect the outcome will be identi fied and included in 
all multivariate models.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 83 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  2. For Part A, Cohort 3 subjects will be stratified by mild versus severe lung disease, 
defined as upper and lower  FEV 1 percentiles and endpoints will be compared across the 
phenotype extremes as well as correlate d with FEV 1 percent predicted as a continuum.  
3. Data will be screened for potential outliers and influential values. In addition, some 
response variables may require log transformation to account for non -constant variance 
or skewness. Either the Mann Whitne y U test or the Wilcoxan Signed Rank test may be 
applied for secondary endpoints for which parametric distributional assumptions do not 
hold.  
4. For select sub -studies, rather than examining mean response or Area  Under the Curve 
(AUC), the primary endpoints w ill be re -examined using a different definition, either as 
change in slope or as percent of responders reaching a pre -defined endpoint.  
5. For Part B, subgroup analysis of the primary endpoint by classifying subjects into 
extreme phenotypes  (e.g., FEV 1 perce ntiles) will help identify markers responsive to 
lumacaftor/ivacaftor .   
13.5 Interim Analysis  
There are no planned interim analyses.  
13.6 Sample Size  
Part A CORE STUDY  
The proposed  number of study subjects to ensure sufficient power to detect a difference in 
sweat  chloride between CFTR groups: 50 per group yields 90% power to detect a difference 
of 15 mmol/L or larger, conservatively assuming a standard deviation of 20 mmol/L in each 
group and ~10% attrition. Additionally, 160 subjects in Cohort 3 will allow for di vision into 
subsets of  lung disease severity (by FEV 1 percentile ) for comparisons, and will provide a 
large enough sample to capture an array of CFTR genotypes  (assuming approximately 60% 
of Cohort 3  subjects will be F508del  homozygotes ). A sample of 210 w ill allow for the 
sufficient banking of biospecimens to support future research that utilizes emerging 
biomarker technologies (e.g., metabolomics and proteomics) to identify novel biomarkers of 
CFTR function, and novel markers of CF lung disease severity.  Data from recent CFF -
supported metabolomics projects indicate that 40 -50 CF subjects per group are necessary to 
validate metabolomics and lipidomics -based biomarkers with a tolerable false discovery 
rate. 
Part A pH pill SUB -STUDY  
Twenty subjects in each c ohort (i.e. Cohorts 2 and 3, for a total of 40 subjects) are required 
to conduct a two -sided t -test with 80% power and type I error at 0.05 to detect a mean 
difference of 0.92 pH (Cohort 3 pH = 4.5 versus Cohort 2 pH = 5.42) assuming a variance 
of 1.0 in e ach group.  
Part B CORE STUDY  
A sample of up to 250 for Part B was chosen based on feasibility to support the six sub -
studies while providing enough power for correlations with potentially subtle changes in 
clinical measures such as FEV 1 and weight or BMI.  Additionally , it will allow for division 
into subsets of  lung disease severity (by FEV 1 percentiles)  for comparisons . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 84 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  Part B GIFT SUB -STUDY  
For the glucose/insulin functional testing: estimates for sample size for OGTT are based on 
data from five G551D CF patients from a recent pilot study for whom AUC data for insulin 
and c -peptide is available pre and one month post ivacaftor .62  Seventy -five subjects ensures 
81% power to detect an increase in AUC insulin of 600 mU/L min at Visit 5 ( approximately  
25% increase assuming baseline mean of 2400 mU/L min , SD =1800 mU/L min) using a 
two-sided paired t -test with alpha 0.05.  Similarly, 75 subjects ensures 82% power to d etect 
an increase in AUC c -peptide of 54 mU/L min at Visit 5 (approx imately  11% increase 
assuming baseline mean of 500 mU/L min , SD =160 mU/L min) using a two -sided paired 
t-test with alpha 0.05.  
For the gastro -intestinal functional testing: assuming 50%  of the sample will have a positive 
breath test at baseline, approximately 35 treated subjects would ensure with 86% probability 
that a 95% CI for SIBO eradication (percent negative at Visit 5) would extend no more than 
±15% from the estimated percent with  a negative breath test, assuming 70% eradication.  
Part B pH pill SUB -STUDY  
Assuming a slightly smaller effect size as that observed in the GOAL pH pill sub -study, a 
sample size of twenty subjects is required to conduct a two -sided paired t -test with 80% 
power and alpha of 0.05 to detect a mean difference of 0.8 pH (Baseline pH = 4.5 versus 
Visit 5 pH = 5.3) assuming a SD of 1.2 for the mean difference.  
Part B MBW/FENO SUB -STUDY  
For MBW: based on previous interventional studies we expect the changes in LCI in 
subjects treated with combination CFTR pharmacotherapy to be similar to the changes in 
subjects treated with hypertonic saline or dornase alfa studies, which were 1 and 0.7 
respectively. Assuming a conservative treatment effect of 0.7 with a standard de viation of 
1.8 (which is higher than what was observed in previous studies as PROSPECT will include 
subjects with a wider range of baseline pulmonary function, where variability may be 
increased) a sample size of 52 would be able to demonstrate the propose d treatment effect 
with 80% power and an alpha of 0.05 in a paired t test analysis. Estimating 30% dropout or 
measurements not of research quality, 6 8 subjects would need to enter the study.  
For FENO:   a small previous interventional study of ivacaftor for  30 days in G551D 
patients observed a change in FENO of 5.2 ppm (SD=3.3). Conservatively assuming 
combination CFTR therapy in homozygous 508del will result in a treatment effect 
approximately 65% smaller (1.8 ppm) with more variability (SD=4.0), a sample s ize of 54 
would be able to demonstrate the proposed treatment effect with 90% power and an alpha of 
0.05 in a paired t test analysis. Estimating 25% dropout or measurements not of research 
quality, 68 subjects would need to enter the study. . 
Part B MCC SUB -STUDY  
Data from the GOAL  study  was used to estimate a required sample size in this similarly 
designed, multicenter study .63  Paired MCC measurements made at 1 and 3 months after 
initiating ivacaftor treatment allowed us to calculate a mean difference in AUC60 values, 
and the standard deviation of this difference (  = 0.11).  We are proposing a treatment 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 85 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  effect size of ~50% that observed in GOAL, given the anticipated smaller degree of CFTR 
functional restoration, or a 5% absolute increase in AUC60.  Forty (40) subjects will allow 
us to have 80% power to detect an effect of this size at an alpha + 0.05 using a  paired, 2 -tail 
t-test.  To account for a 10% dropout rate, 44 subjects would be needed to enter this MCC 
sub-study.  Of note, the AUC60 variable was interpretable in every subject during the 
GOAL study, so no further inflation of sample size is being made  to adjust for inadequate 
quality of research data.  
14 DATA COLLECTION, RET ENTION AND CLINICAL MONITORING  
14.1 Data Collection Instruments  
The Investigator will prepare and maintain adequate and accurate source documents 
designed to record all observations and oth er pertinent data for each subject who is enrolled 
in the study.    
Study personnel at each site will enter data from source documents corresponding to a 
subject’s visit into the protocol -specific electronic Case Report Form (CRF ) when  the 
information corre sponding to that visit is available.  Subjects will not be identified by name 
in the study database or on any study documents to be collected by the Sponsor (or 
designee), but will be identified by a site number, subject number , and initials.  
If a correcti on is required for a CRF, the  time and date stamps track the person entering or 
updating CRF data and create an electronic audit trail.   
The Investigator is responsible for all information collected on subjects enrolled in this 
study.  All data collected during the course of this study must be reviewed and verified for 
completeness and accuracy by the Investigator.  A CD containing the CRF data will be 
provided to the site to retain with the essential documents at the Investigator’s site at the 
completion of the study.  
Subjects who are participating in the various sub -studies will keep  the same unique 
identification number as the CORE study.  Sub-study specific data ( e.g., MCC images, 
MBW results, pH pill results) generally will not be entered into the CRF  but will be 
provided directly by participating sites to the sub -study principal investigator for evaluation 
and analysis via secure mail or electronic transfer.  The data files will be kept on a password 
protected computer and routinely backed up.  At the  end of the study, the sub -study 
principal investigators will provide relevant sub -study data to the TDNCC to be 
incorporated into the overall study database and will be transferred via the secure Accellion 
file transfer application.  Similarly the TDNCC w ill provide each of the sub -study principal 
investigators with relevant data for sub -study subjects from the CRF for their sub -study 
specific analyses. Relevant d ata from subjects co -enrolled in the Part B CORE study and the 
PUSH study will be  exchanged be tween PROSPECT and PUSH study principal 
investigators via secure mail or electronic transfer . Details of the data transfer (including, 
but not limited to, frequency of transfer, format of data and query process) will be 
documented in a Data Transfer Agreem ent between each of the research labs/sub -study 
principal investigator institutions   (including  the PUSH investigator(s)/ institution (s) 
receiving PROSPECT data ) and the TDNCC . 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 86 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  14.2 Data Management Procedures  
TDNCC utilizes Medidata Solutions, Inc. (Medidata) Ra ve® for their electronic data capture 
(EDC) studies. The Medidata Rave EDC system is designed to be US Code of Federal 
Regulations (CFR) 21 Part 11 compliant with a robust audit trail system and electronic 
signature capabilities.  Study personnel at each s ite will enter data from a subject’s visit 
onto electronic CRF screens via a web browser.  Study subjects will not be identified by 
name in the study database or on any data capture screens, but will be identified by initials 
and a unique subject identific ation number.  Only study personnel at the individual sites will 
be able to link the study ID to the subject’s name.  The Data Management group of the 
TDNCC will be responsible for data processing, in accordance with procedural 
documentation.  Database loc k will occur once quality assurance procedures have been 
completed.  All procedures for the handling and analysis of data will be conducted using 
good computing practices for the handling and analysis of data for clinical trials.   
Data Quality Control and  Reporting : After data have been entered into the study database, a 
system of computerized data validation checks will be implemented and applied to the 
database on a regular basis. Queries are entered, tracked, and resolved through the EDC 
system directly .  The study database will be updated in accordance with the resolved 
queries.  All changes to the study database will be documented.  
14.3 Security and Archival of Data  
The EDC system is hosted by Medidata; the data are stored at Medidata’s primary data 
center in Houston, Texas, with fail -safe data centers in New Jersey.  Data are regularly 
backed up by Medidata and stored with Iron Mountain.  
Medidata maintains 21 CFR Part 11 -compliant electronic systems, with procedures in place 
to safeguard against unauthorize d acquisition of data.  Any authorized communication with 
the Medidata servers at the Houston Data Center is conducted via SSL (128 -bit) encryption.  
Robust password procedures,  consistent with 21 CFR Part 11, are in place.  Robust physical 
security procedu res are in place at the Houston Data Center to prevent unauthorized 
personnel physical access to the server rooms.  EDC account access is maintained and 
monitored by the Data Management group of the TDNCC.  
Other databases will be stored on Seattle Children ’s servers and are safeguarded against 
unauthorized access by established security procedures.  Network accounts are password 
protected and maintained and monitored by the Seattle Children’s Research Institute 
Information Technology group.  Data is backed up regularly according to the Information 
Technology group’s procedures.  
Note that there is an intention to make biospecimens and associated data available to 
investigators for future exploration. The biospecimens will be collected under IRB approval, 
processed according to a rigorous standard operating procedure and stored at a central 
facility, with appropriate procedures to enable long term, stable storage. Researchers may 
apply, via a standardized process, for use of de -identified data and specimens fo r research 
purposes. Applications will undergo a scientific review process administered through CFFT. 
When applying for use of data or specimens, the applicant must agree to: (1) use the data 
and specimens only for research purposes and to not make any att empts to try to identify 
any individual subject; (2) securing the data and specimens using appropriate methods; and 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 87 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  (3) destroy or return the data (and specimens) in accordance with the specimen/data use 
agreement after analyses are completed.  Before data  or specimens will be released to an 
investigator, documentation of IRB exemption or approval from their institution must be 
provided to the CFFT.  
14.4 Availability and Retention of Investigational Records  
The Investigator must make study data accessible to the  monitor, other authorized 
representatives of the Sponsor (or designee), IRB/IEC, and Regulatory Agency (e.g., FDA) 
inspectors upon request.  A file for each subject must be maintained that includes the signed 
Informed Consent, HIPAA Authorization , Assent Form , and copies of all source 
documentation related to that subject.  The Investigator must ensure the reliability and 
availability of source documents from which the information on the CRF was derived.  
All study documents (e.g., subject  files, signed inf ormed consent forms, CD copy of CRF 
data, Essential Document and Study Reference Binders) must be kept secured on site for a 
period of one year after database lock and accessible until publication of the primary study 
results has occurred .  There may be ot her circumstances for which the Sponsor is required 
to maintain study records and, therefore, the Sponsor should be contacted prior to removing 
study records for any reason.  
14.5 Monitoring  
By signing this protocol, the Investigator grants permission to the Spo nsor (or designee), 
and appropriate regulatory authorities to conduct on -site monitoring and/or auditing of all 
appropriate study documentation.     
14.6 Subject Confidentiality  
In order to maintain subject confidentiality, only a site number, subject number , and subject 
initials will identify all study subjects on CRFs and other docume ntation submitted to the 
Sponsor, study PIs or Sponsor representatives .   The subject’s CFF patient registry  number 
will also be collected. Additional subject confidentiality issu es (if applicable) are covered in 
the Clinical Study Agreement.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 88 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  15 ADMINISTRATIVE, ETHI CAL, REGULATORY CONS IDERATIONS  
The study will be conducted according to the Declaration of Helsinki, Protection of Human 
Volunteers (21 CFR 50), Institutional Review Board s (21 CFR 56), and Obligations of 
Clinical Investigators (21 CFR 312).  
To maintain confidentiality, all laboratory specimens, evaluation forms, reports and other 
records will be identified by a coded number and initials only.  Clinical information will not  
be released without written permission of the subject, except as necessary for monitoring by 
the FDA.  The Investigator must also comply with all applicable privacy regulations (e.g., 
Health Insurance Portability and Accountability Act of 1996, EU Data Pr otection Directive 
95/46/EC).  
15.1 Protocol Amendments  
Any amendment to the protocol will be written by the Sponsor.   Protocol amendments 
cannot be implemented without prior written IRB/IEC approval except as necessary to 
eliminate immediate safety hazards to subjects .  A protocol amendment intended to 
eliminate an apparent immediate hazard to subjects  may be implemented immediately, 
provided the IRBs are notified within five working days . 
15.2 Institutional Review Boards and Independent Ethics Committees  
The protoco l and consent form will be reviewed and approved by the IRB/IEC of each 
participating center prior to study initiation.  SAEs related to study procedures will be 
reported to the IRB/IEC in accordance with the standard operating procedures and policies 
of the IRB/IEC, and the Investigator will keep the IRB/IEC informed as to the progress of 
the study.  The Investigator will obtain assurance of IRB/IEC compliance with regulations.  
Any documents that the IRB/IEC may need to fulfill its responsibilities (such a s protocol, 
protocol amendments, consent forms, information concerning subject  recruitment, payment 
or compensation procedures, or other pertinent information) will be submitted to the 
IRB/IEC.  The IRB/IECs written unconditional approval of the study prot ocol and the 
informed consent form will be in the possession of the Investigator before the study is 
initiated.  The IRB/IEC ’s unconditional approval statement will be transmitted by the 
Investigator to the Sponsor or designee prior to the  shipment of stud y supplies to the site.  
This approval must refer to the study by exact protocol title and number and should identify 
the documents reviewed and the date of review.  
Protocol and/or informed consent modifications or changes may not be initiated without 
prior written IRB/IEC approval except when necessary to eliminate immediate hazards to 
the subject s or when the change(s) involves only logistical or administrative aspects of the 
study.  Such modifications will be submitted to the IRB/IEC and written verifica tion that 
the modification was submitted and subsequently approved should be obtained.   
The IRB/IEC must be informed of revisions to other documents originally submitted for 
review; serious and/or unexpected AEs related to study procedures  occurring durin g the 
study in accordance with the standard operating procedures and policies of the IRB; new 
information that may affect adversely the safety of the subjects  or the conduct of the study; 
an annual update and/or request for re -approval; and when the study has been completed.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 89 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  15.3 Informed Consent Form  
Informed consent will be obtained in accordance with the Declaration of Helsinki, ICH 
GCP, US Code of Federal Regulations for Protection of Human Subjects (21 CFR 
50.25[a,b], CFR 50.27, and CFR Part 56, Subpart A) , the Health Insurance Portability and 
Accountability Act (HIPAA ), if applicable, and local regulations.  
The Investigator will prepare the informed consent form, assent and HIPAA authorization 
and provide the documents to the Sponsor or designee for approv al prior to submission to 
the IRB/IEC.  The consent form generated by the Investigator must be acceptable to the 
Sponsor and be approved by the IRB/IEC.  The written consent document will embody the 
elements of informed consent as described in the Internat ional Conference on 
Harmonisation and will also comply with local regulations. The Investigator will send an 
IRB/IEC -approved copy of the Informed Consent Form to the Sponsor (or designee) for the 
study file.  
A properly executed, written, informed consent will be obtained from each subject prior to 
entering the subject into the trial.  Information should be given in both oral and written form 
and subjects (or their legal representatives) must  be given ample opportunity to inquire 
about details of the study.   If appropriate and required by the local IRB/IEC, assent from the 
subject will also be obtained.  If a subject is unable to sign the informed consent form ( ICF) 
and the HIPAA authorization, a legal representative may sign for the subject.   A copy of 
the signed consent form (and assent) will be given to the subject or legal representative of 
the subject and the original will be maintained with the subject’s records . 
During the course of the study, if modifications are made to the consent form that impact 
the subject, the subject will be re -consented as described above.  
15.3.1  Collection and Use of CFF Registry ID Number  
To facilitate possible future evaluation of retrospective and prospective information from all 
patients who screen for this study, the subject’s  CFF Registry ID number will be collected 
at Visit 1 or 4 (as applicable) .  The CFF registry collects data on all CF patients who 
consented to participate in the CFF registry  and who are  followed at CFF -accredited care 
centers .  The registry data includes information from  clinical encounter s, hospitalization s, 
course s of antibiotics, and year -end survey s.  Data also include microbiology results, 
spirometry results, CF genotype and other information. The subject ’s CF registry number 
will be recorded in the C RF. 
15.4 Publications  
The preparation and submittal for publication of manuscripts containing the study results 
shall be in accordance with a process determined by mutual written agreement between 
Seattle Children’s Research Institute and participating institu tions.  The publication or 
presentation of any study results shall comply with all applicable privacy laws, including, 
but not limited to, HIPAA .  
15.5 Investigator Responsibilities  
By signing the Agreement of Investigator form, the Investigator agrees to:  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 90 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  1. Cond uct the study in accordance with the protocol and only make changes after 
notifying the Sponsor (or designee), except when to protect the safety, rights or welfare 
of subjects.  
2. Personally conduct or supervise the study (or investigation).  
3. Ensure that the r equirements relating to obtaining informed consent and IRB review 
and approval meet federal guidelines, as stated in §21 CFR, parts 50 and 56.  
4. Report to the Sponsor or designee any AEs  related to study procedures  that occur in the 
course of the study, in a ccordance with §21 CFR 312.64.  
5. Ensure that all associates, colleagues and employees assisting in the conduct of the 
study are informed about their obligations in meeting the above commitments.  
6. Maintain adequate and accurate records in accordance with §21 C FR 312.62 and to 
make those records available for inspection with the Sponsor (or designee).  
7. Ensure that an IRB that complies with the requirements of §21 CFR part 56 will be 
responsible for initial and continuing review and approval of the clinical study.  
8. Promptly report to the IRB and the Sponsor (or designee) all changes in the research 
activity and all unanticipated problems involving risks to subjects or others (to include 
amendments and IND safety reports).  
9. Seek IRB approval before any changes are mad e in the research study, except when 
necessary to eliminate hazards to the patients/subjects.  
10. Comply with all other requirements regarding the obligations of clinical investigators 
and all other pertinent requirements listed in § 21 CFR part 312.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 91 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  16. REFE RENCES:  
1. Sloane PA, Rowe SM. Cystic fibrosis transmembrane conductance regulator protein 
repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med. 2010; 16(6): 
591-7. 
2. Paranjape SM, Zeitlin PL. Atypical cystic fibrosi s and CFTR -related diseases. Clin Rev 
Allergy Immunol. 2008; 35(3): 116 -23. 
3. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, et al. Genetic 
modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005; 353(14): 1443 -53. 
4. Cutting GR. Modifier genetics: cystic fibrosis. Annu Rev Genomics Hum Genet. 2005; 
6: 237 -60. 
5. Ooi CY, Dorfman R, Cipolli M, Gonska T, Castellani C, Keenan K, et al. Type of 
CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. 
Gastroentero logy. 2011; 140(1): 153 -61. 
6. Kopelman H, Durie P, Gaskin K, Weizman Z, Forstner G. Pancreatic fluid secretion 
and protein hyperconcentration in cystic fibrosis. N Engl J Med. 1985; 312(6): 329 -34. 
7. Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH a nd gastrointestinal transit 
profiles in cystic fibrosis patients measured by wireless motility capsule. Dig Dis Sci. 
2013; 58(8): 2275 -81. 
8. Couper RT, Corey M, Moore DJ, Fisher LJ, Forstner GG, Durie PR. Decline of 
exocrine pancreatic function in cystic fibrosis patients with pancreatic sufficiency. 
Pediatr Res. 1992; 32(2): 179 -82. 
9. Wong LT, Turtle S, Davidson AG. Secretin pancreozymin stimulation test and 
confirmation of the diagnosis of cystic fibrosis. Gut. 1982; 23(9): 744 -50. 
10. Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of 
VX-770 in persons with cystic fibrosis and the G551D -CFTR mutation. N Engl J Med. 
2010; 363(21): 1991 -2003.  
11. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. A CFTR 
potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 
2011; 365(18): 1663 -72. 
12. Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, et al. 
Efficacy and safety of ivacaftor in patients aged 6 to 11 years wi th cystic fibrosis with a 
G551D mutation. Am J Respir Crit Care Med. 2013; 187(11): 1219 -25. 
13. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, et al. A 
CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of 
patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 
randomised controlled trial. The lancet Respiratory medicine. 2014.  
14. Vertex Pharmaceuticals I. Two 24 -Week Phase 3 Studies of Lumacaftor in 
Combination with Ivacaftor Met Primary En dpoint with Statistically Significant 
Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two 
Copies of the F508del Mutation.  2014  ; Available from: 
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185  
15. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in 
patients with cystic fibrosis. N Engl J Med. 1992; 326(18): 1187 -91. 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 92 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  16. de Jong PA, Lindblad A, Rubin L, Hop WC, de  Jongste JC, Brink M, et al. Progression 
of lung disease on computed tomography and pulmonary function tests in children and 
adults with cystic fibrosis. Thorax. 2006; 61(1): 80 -5. 
17. Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistr ibution as an 
early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003; 
22(6): 972 -9. 
18. Aurora P, Gustafsson P, Bush A, Lindblad A, Oliver C, Wallis CE, et al. Multiple 
breath inert gas washout as a measure of ventilation dist ribution in children with cystic 
fibrosis. Thorax. 2004; 59(12): 1068 -73. 
19. Horsley AR, Gustafsson PM, Macleod KA, Saunders C, Greening AP, Porteous DJ, et 
al. Lung clearance index is a sensitive, repeatable and practical measure of airways 
disease in ad ults with cystic fibrosis. Thorax. 2008; 63(2): 135 -40. 
20. Gustafsson PM, De Jong PA, Tiddens HA, Lindblad A. Multiple -breath inert gas 
washout and spirometry versus structural lung disease in cystic fibrosis. Thorax. 2008; 
63(2): 129 -34. 
21. Owens CM, Au rora P, Stanojevic S, Bush A, Wade A, Oliver C, et al. Lung Clearance 
Index and HRCT are complementary markers of lung abnormalities in young children 
with CF. Thorax. 2011; 66(6): 481 -8. 
22. Hall GL, Logie KM, Parsons F, Schulzke SM, Nolan G, Murray C, et  al. Air trapping 
on chest CT is associated with worse ventilation distribution in infants with cystic 
fibrosis diagnosed following newborn screening. PLoS One. 2011; 6(8): e23932.  
23. Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, et al. Lu ng 
clearance index at 4 years predicts subsequent lung function in children with cystic 
fibrosis. Am J Respir Crit Care Med. 2011; 183(6): 752 -8. 
24. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, et al. Hypertonic 
saline improves the LCI i n paediatric patients with CF with normal lung function. 
Thorax. 2010; 65(5): 379 -83. 
25. Amin R, Subbarao P, Lou W, Jabar A, Balkovec S, Jensen R, et al. The effect of 
dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J. 
2011; 37(4): 806 -12. 
26. Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, et al. Assessment 
of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients 
with a G551D -CFTR mutation and preserved spirometry: a ra ndomised controlled trial. 
The lancet Respiratory medicine. 2013; 1(8): 630 -8. 
27. Boon M, Meyts I, Proesmans M, Vermeulen FL, Jorissen M, DeBoeck K. Diagnostic 
accuracy of nitric oxide measurements to detect primary ciliary dyskinesia. Eur J Clin 
Invest. 2014; 44(5): 477 -85. 
28. Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, et al. Exhaled 
nitric oxide in pulmonary diseases: a comprehensive review. Chest. 2010; 138(3): 682 -
92. 
29. Grasemann H, Michler E, Wallot M, Ratjen F. Decreased conc entration of exhaled 
nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol. 1997; 24(3): 173 -7. 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 93 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  30. Keen C, Gustafsson P, Lindblad A, Wennergren G, Olin AC. Low levels of exhaled 
nitric oxide are associated with impaired lung function in cys tic fibrosis. Pediatr 
Pulmonol. 2010; 45(3): 241 -8. 
31. Gaston B, Ratjen F, Vaughan JW, Malhotra NR, Canady RG, Snyder AH, et al. 
Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal 
therapy. Am J Respir Crit Care Med. 2002; 165(3): 387 -90. 
32. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An 
official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels 
(FENO) for clinical applications. Am J Respir Crit Care Med. 2011; 184(5): 6 02-15. 
33. Donaldson SH, Boucher RC. Update on pathogenesis of cystic fibrosis lung disease. 
CurrOpinPulmMed. 2003; 9(6): 486 -91. 
34. Quinton PM. Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. 
Lancet. 2008; 372(9636): 415 -7. 
35. Hender son AG, Ehre C, Button B, Abdullah LH, Cai LH, Leigh MW, et al. Cystic 
fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic 
pressure. The Journal of clinical investigation. 2014.  
36. Mall M, Grubb BR, Harkema JR, O'Neal WK, Bou cher RC. Increased airway epithelial 
Na+ absorption produces cystic fibrosis -like lung disease in mice. NatMed. 2004; 
10(5): 487 -93. 
37. Bennett W, Zeman K, Donaldson SH, Donohue JF, Knowles MR, Boucher RC. Cough 
Clearance is Less Effective in Cystic Fibro sis than Chronic Bronchitis. 
AmJRespCritCare Med. 2004; 169(7): A386.  
38. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus 
clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 
2006; 354(3): 241 -50. 
39. Jakab RL, Collaco AM, Ameen NA. Physiological relevance of cell -specific 
distribution patterns of CFTR, NKCC1, NBCe1, and NHE3 along the crypt -villus axis 
in the intestine. Am J Physiol Gastrointest Liver Physiol. 2011; 300(1): G82 -98. 
40. Strong TV, Boehm K, Collins FS. Localization of cystic fibrosis transmembrane 
conductance regulator mRNA in the human gastrointestinal tract by in situ 
hybridization. The Journal of clinical investigation. 1994; 93(1): 347 -54. 
41. Clarke LL, Harline MC. Dual role of CFTR in cAMP -stimulated HCO3 - secretion 
across murine duodenum. Am J Physiol. 1998; 274(4 Pt 1): G718 -26. 
42. Pezzulo AA, Tang XX, Hoegger MJ, Alaiwa MH, Ramachandran S, Moninger TO, et 
al. Reduced airway surface pH impairs bacterial killing in the porcine  cystic fibrosis 
lung. Nature. 2012; 487(7405): 109 -13. 
43. De Lisle RC. Altered transit and bactgerial overgrowth in the cystic fibrosis mouse 
small intestine. Am J Physiol Gastrointest Liver Physiol. 2007; 293(1): G104 -11. 
44. Duytschaever G, Huys G, Bek aert M, Boulanger L, De Boeck K, Vandamme P. 
Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal 
microbiota. J Cyst Fibros. 2013; 12(3): 206 -15. 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 94 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  45. Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, et al. 
Escherichia coli dysbiosis correlates with gastrointestinal dysfunction in children with 
cystic fibrosis. Clin Infect Dis. 2014; 58(3): 396 -9. 
46. Schippa S, Iebba V, Santangelo F, Gagliardi A, De Biase RV, Stamato A, et al. Cystic 
fibrosis transmembrane cond uctance regulator (CFTR) allelic variants relate to shifts in 
faecal microbiota of cystic fibrosis patients. PLoS One. 2013; 8(4): e61176.  
47. Singh VV, Toskes PP. Small bowel bacterial overgrowth: presentation, diagnosis, and 
treatment. Curr Gastroenterol  Rep. 2003; 5(5): 365 -72. 
48. Fridge JL, Conrad C, Gerson L, Castillo RO, Cox K. Risk factors for small bowel 
bacterial overgrowth in cystic fibrosis. J Pediatr Gastroenterol Nutr. 2007; 44(2): 212 -
8. 
49. Lewindon PJ, Robb TA, Moore DJ, Davidson GP, Martin  AJ. Bowel dysfunction in 
cystic fibrosis: importance of breath testing. J Paediatr Child Health. 1998; 34(1): 79 -
82. 
50. Lee JM, Leach ST, Katz T, Day AS, Jaffe A, Ooi CY. Update of faecal markers of 
inflammation in children with cystic fibrosis. Mediator s Inflamm. 2012; 2012 (948367): 
1-6. 
51. Smyth RL, Croft NM, O'Hea U, Marshall TG, Ferguson A. Intestinal inflammation in 
cystic fibrosis. Arch Dis Child. 2000; 82(5): 394 -9. 
52. Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, et al. Evidence of  chronic 
inflammation in morphologically normal small intestine of cystic fibrosis patients. 
Pediatr Res. 2000; 47(3): 344 -50. 
53. Werlin SL, Benuri -Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, et al. 
Evidence of intestinal inflammation in patient s with cystic fibrosis. J Pediatr 
Gastroenterol Nutr. 2010; 51(3): 304 -8. 
54. Rumman N, Sultan M, El -Chammas K, Goh V, Salzman N, Quintero D, et al. 
Calprotectin in cystic fibrosis. BMC Pediatr. 2014; 14: 133.  
55. Garcia -Sanchez V, Iglesias -Flores E, Gonza lez R, Gisbert JP, Gallardo -Valverde JM, 
Gonzalez -Galilea A, et al. Does fecal calprotectin predict relapse in patients with 
Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010; 4(2): 144 -52. 
56. Lisowska A, Madry E, Pogorzelski A, Szydlowski J,  Radzikowski A, Walkowiak J. 
Small intestine bacterial overgrowth does not correspond to intestinal inflammation in 
cystic fibrosis. Scand J Clin Lab Invest. 2010; 70(5): 322 -6. 
57. Bruzzese E, Callegari ML, Raia V, Viscovo S, Scotto R, Ferrari S, et al. Disrupted 
intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its 
restoration with Lactobacillus GG: a randomised clinical trial. PLoS One. 2014; 9(2): 
e87796.  
58. Gelfond D, Borowitz D, Frederick CA, Uluer AZ, Sicilian L,  Konstan MW, et al. 
Impact of ivacaftor therapy on the intestinal pH profile in CF subjects with G551D 
mutation. Pediatr Pulmonol. 2013; 48: 405 (abstract).  
59. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis related 
diabetes: curr ent trends in prevalence, incidence and mortality . Diabetes Care. 
2009; 32: 1626 -31. 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 95 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  60. Moran A, Becker D, Casella SJ, Gottlieb PA, Kirkman MS, Marshall BC, et al. 
Epidemiology, pathophysiology and prognstic implications of CFRD: a technical 
review. Diabe tes Care. 2010; 33: 2677 -83. 
61. Hammana I, Coderre I, Potvin S, Costa M, Berthiaume Y, Lavoie A, et al. Dichotomy 
between postprandial glucose and lipid profiles in adults with CF: a pilot study. J 
Cystic Fibrosis. 2009; 8: 128 -34. 
62. Bellin MD, Laguna T , Leschyshyn J, Regelmann W, Dunitz J, Billings J, et al. Insulin 
secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small 
pilot study. Pediatr Diabetes. 2013; 14(6): 417 -21. 
63. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Bor owitz D, Gelfond D, et al. 
Clinical Mechanism of the Cystic Fibrosis Transmembrane Conductance Regulator 
Potentiator Ivacaftor in G551D -mediated Cystic Fibrosis. Am J Respir Crit Care Med. 
2014; 190(2): 175 -84. 
 
 
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 96 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  APPENDIX 1:  SCHEDUL E OF EVENTS - PART A ( COHORT 1 : NORMAL 
CONTROLS)  
 VISIT 1 a 
Day 0 VISIT 2 a 
Day 14 ( ±7 days) 
Informed Consent  
 Study  
 Optional DNA banking  X  
Pre-Visit Reminder Call  X X 
Medical History  X  
Review E ligibility  X  
Demographics  X  
Urine P regnancyb X X 
Menstrual Cycle T imingb X X 
Concomitant Medication Review  X X 
Height  X  
Weight  X  
Clinical Laboratory Testing  
 CBC with Differential  X  
Biorepository Specimen Collection  
 Urine  
 Blood:  
o Serum  
o EDTA Plasma  
o Buffy Coat ( w/ DNA Consent)  X X 
Sweat Specimen Collection (Macroduct)  X  
Dispense Stool Collection Kitc X  
Obtain Fecal Specimen  
 Elastase /Calprotectin   
 Biorepository   X 
Adverse Events (related to study procedures)  X X 
Nasal Cell Procurement Procedure d X X  
 
a  Subjects w ill be  fasting for 6 hours prior to all visits. Vi sit scheduling will need to take this into account.   
b  Only females of child -bearing potential.  
c  Fecal collection kits will be provided to subjects with instructions on how to collect and freeze at home and return 
samples to the clinic at Visit 2.  
d       Nasal epithelial cell samples will be collected at selected centers with the capability to do the test and from subjects 
who have provided consent for DNA samples. The procedure is not visit specific and can be collected at any visit when 
convenient .  
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 97 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  APPENDIX 2:  SCHEDUL E OF EVENTS - PART A (COHORTS 2 AN D 3) 
 
 
VISIT 1a 
DAY 0 VISIT 2a,b VISIT 3a,b,c 
MONTH 3  
(90 Days ±30 days)  Day 14  
(±7 days)  CALL 2Bk  
(+1 day)    
PART A CORE STUDY  
Informed Consent  
 CORE Study  
o Optional DNA banking   
 pH Pill Sub -Study (optional)  X    
Medical History  X    
Pre-Visit Reminder Call  X X  X 
Confirm Eligibility  X    
Demographics and CFF Registry ID  X    
CF Diagnosis  and Genotype  X    
Historic OGTT Result  X    
Historic Fecal Elastase Resultd X    
Urine P regnancye X X  X 
Menstrual Cycle T iminge X X  X 
Clinical Status Review  X X  X 
Concomitant Medication Review  X X  X 
Height  X X  X 
Weight  X X  X 
Clinical Laboratory Testing  
 Chemistryf 
 Hemoglobin A1C  X    
Clinical Laboratory Testing  
 CBC with Differential  X X  X 
Biorepository Specimen Collection  
 Urine  
 Blood:  
o Serum  
o EDTA Plasma  
o Buffy Coat ( w/ DNA Consent)  X X  X 
Dispense Stool Collection Kit  X X   
Obtain Fecal Specimeng 
 Elastase/Calprotectin  
 Biorepository   X  X 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 98 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   
VISIT 1a 
DAY 0 VISIT 2a,b  VISIT 3a,b,c 
MONTH 3  
(90 Days ±30 days)  Day 14  
(±7 days)  CALL 2Bk  
(+1 day)    
Nasal Epithelial Cell Procurementh X    
Administer short -acting bronchodilator  X X  X 
Spirometryi X X  X 
Sputum Specimen Collection ( Induction 
Procedure )j 
 Inflammatory Mediators  
 Microbi ome  
 Biorepository  X X   
Sweat Specimen Collection  
(Macroduct)  X X  X 
Adverse Events (related to study 
procedures)  X X  X 
PH PILL SUB -STUDY (OPTIONAL)  
Remind Subject of Study Requirements 
Pre-pH Pill   X   
Confirm Eligibility   X   
Perform GI assessme nt  X   
Abdominal Exam   X   
Modified symptom sub -scale CFQR   X   
Swallow pH Pill with GlucoCrush   X   
Provide Instructions and Mailer   X   
Call to assess use of Monitor and 
Review GI Symptoms    X  
a  Subjects w ill be fasting for 6 hours prior to all visits. Visit scheduling will need to take this into account.    
b       If subject comes in with symptoms of a pulmonary exacerbation requiring treatment, is currently being or has recently  been treated 
for a pulmonary exacerbation , reschedule the subject to return for the study visit two weeks after completion of the acute systemic 
therapies.  
c  For subjects participating in PART B, Visit 3 may be skipped.  
d  Record the most recent fecal elastase result. For subjects in Cohort 2 only; if no historic value is available from within the last 5 
years, conduct this test locally and report the value in the CRF.  
e  Only females of child -bearing potential  
f  BUN, creatinine, albumin, aspartate aminotransferase (AST/SGOT), alanine am inotransferase (ALT/SGPT), and gamma -glutamyl 
transferase (GGT).   
g  Fecal collection kits will be provided to subjects with instructions on how to collect and freeze at home and return samples to the 
clinic at Visits 2 and 3, respectively.  
h   Nasal epithelial cell samples will be coll ected at sites with the capability to perform the collection and  from subjects who have 
provided consent for DNA samples.  The procedure is not visit specific, should only be performed once per subject at which ever 
visit is deemed most convenient.  
i  The spirometry procedure should be performed in concert with the sputum induction procedure to occur after short -acting 
bronchodilator administration and prior to the sputum induction itself.  All spirometry testing should be performed between 1 5 ±5 
minutes po st-bronchodilator administration.  
j  Before conducting the sputum induction procedure, confirm that the subject meets the criteria to perform the procedure (no hi story 
of massive hemoptysis within 72 hours of the procedure, pre -albuterol spirometry FEV1 is  >30% of predicted, and able to tolerate 
procedure).  If the induction procedure cannot be performed and if the subject can expectorate good quality sputum sample (de fined 
as a minimum 0.5 mL sputum volume with visible mucus plugs), expectorated sputum wil l be obtained.   
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 99 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  APPENDIX 3: SCHEDULE OF EVENTS  – PART B  
 VISIT 4 VISIT 5  VISIT 6 
 
3 MONTHS   
post DAY 1 
(90 Days ±30 
days) VISIT 7 
 
6 MONTHS  
post DAY 1 
(180 Days ±30 
days) VISIT 8  
 
12 MONTHS  
post DAY 1  
(360 Days ±30 
days) PRE -VISIT 
4Ab VISIT 4 b   
Up to 30 
days  
prior to 
DAY 1c VISIT 4B a 
24 (±6) 
hours  
post VISIT 
4 VIST 5 a    
30 days 
post DAY 1 
(±7 days) VISIT 5B a 
24 (±6) 
hours  
post VISIT 
5 
PART B CORE STUDY  
Confirm Eligibility   X       
Informed Consent  
 Part B CORE Study   
o Optional DNA coll ection  
o Optional PUSH d ata sharing  
 Optional Sub -Study Consent:  
o GIFT Sub -Studyb 
o pH Pill Sub -Studyb 
o MBW/FENO Sub -Study  
o MCC  Sub- Studyb Xb X       
Demographics and CFF Registry IDd  X       
CF Diagnosis d and Genotype  X       
Menstrual Cycle T iminge  X  X  X X X 
Clinical Status Review   X  X  X X X 
Limited Concomitant Medication Review   X  X  X X X 
Height   X  X  X X X 
Weight   X  X  X X X 
Clinical Laboratory Testing  
 CBC with Differential   X  X  X X X 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 100 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   VISIT 4 VISIT 5  VISIT 6 
 
3 MONTHS   
post DAY 1 
(90 Days ±30 
days) VISIT 7 
 
6 MONTHS  
post DAY 1 
(180 Days ±30 
days) VISIT 8  
 
12 MONTHS  
post DAY 1  
(360 Days ±30 
days) PRE -VISIT 
4Ab VISIT 4 b   
Up to 30 
days  
prior to DAY 
1c VISIT 4B a 
24 (±6) 
hours  
post VISIT 
4 VIST 5 a    
30 days 
post DAY 1 
(±7 days) VISIT 5B a 
24 (±6) 
hours  
post VISIT 
5 
Biorepository Specimen Collection  
 Urine  
 Blood:  
 Serum  
 EDTA Plasma  
 Buffy Coat (w/DNA Consent)   
X  X  X X X 
Nasal Epithelial Cell Procurementf  X        
Administer short -acting bronchodilator   X  X  X X X 
Spirometryg  X  X  X X X 
Sputum Specimen Collection (Induction 
Procedure)h 
 Inflammatory Mediators  
 Microbiome  
 Biorepository   
X  X   X X 
Sweat Specimen Collection ( Macroduct )    X  X  X X X 
Adverse Events (related to study 
procedures)   X X X X X X X 
 
         
         
         
         
         
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 101 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   VISIT 4 VISIT 5 VISIT 6 
 
3 MONTHS  
post DAY 1 
(90 Days ±30 
days)  VISIT 7 
 
6 MONTHS  
post DAY 1 
(180 Days ±30 
days)  VISIT 8 
 
12 MONTHS  
post DAY 1  
(360 Days ±30 
days)  PRE -VISIT 
4Ab VISIT 4 b 
Up to 30 
days 
prior to DAY 
1c VISIT 4B a 
24 (±6) 
hours  
post VISIT 
4 VIST 5 a 
30 days 
post  DAY 1 
(±7 days)  VISIT 5B a 
24 (±6) 
hours  
post VISIT 
5 
GIFT SUB -STUDY a,m 
Remind subject of study requirements 
pre-OGTTi X   X   X X 
Confirm eligibility  X X       
Dispense  stool collection kit j X   X     
Obtain frozen fecal specimen  
 Calprotectin  
 Biorepository    X    X   
Place saline trap or heparin lock   X  X   X X 
HbA1c   X     X X 
Dispense 3 -Day Insulin Diary  X X    X X  
Record insulin use    X  X   X X 
Breath hydro gen Test Collectionk  X  X     
2 HR Oral GTT n, o, p  X  X   X X 
 
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 102 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012   VISIT 4 VISIT 5 VISIT 6 
 
3 MONTHS   
post DAY 1 
(90 Days ±30 
days) VISIT 7 
 
6 MONTHS  
post DAY 1 
(180 Days ±30 
days) VISIT 8 
 
12 MONTHS  
post DAY 1  
(360 Days ±30 
days) PRE -VISIT 
4Ab VISIT 4 b 
Up to 30 
days  
prior to 
DAY 1c VISIT 4B a 
24 (±6) 
hours  
post VISIT 
4 VIST 5 a 
30 days 
post DAY 1 
(±7 days) VISIT 5B a 
24 (±6) 
hours  
post VISIT 
5 
PH PILL SUB -STUDY (SUBSET OF GIF T SUBJECTS)a,m 
Remind subject of study requirements pre -
pH Pill t esti X   X     
Confirm Eligibility  X X       
Urine Pregnancye  X  X     
GI Assessment   X  X     
Abdominal Exam   X  X     
Modified symptom sub -scale  CFQR   X  X     
Swallow pH Pill with GlucoCrushq,r,  X  X x     
Provide instructions and mailer   X  X     
Confirm use of monitor and review GI 
symptoms    X  X    
MBW/FENO SUB -STUDY m 
Confirm Eligibility   X       
Multiple Breath Washout Procedure   X  X  X X X 
Fractional Exhaled NOs  X  X   X  
MCC  SUB -STUDY (SUBSET OF MBW/FENO SUBJECTS) m 
Remind subj ect of study requirements pre -
MCC test t X   X     
Confirm eligibility  X X       
Urine pregnancye  X  X     
Perform MCC Procedure,v, w  X X X u X    
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 103 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  a  For the GIFT Sub -study all visits should be conducted first thing in the morning, as subjects will  be fasting for 8 hours prior to all visits to accommodate the OGTT 
requirements . 
b  Subjects must be consented prior to Visit 4 for the GIFT, MCC and pH Pill sub -studies (all require holding of some medications).  
c  Day 1 is designated as the start of trea tment with lumacaftor/ivacaftor.  
d  Collected for subjects who did not participate in PART A.  
e  Only females of child -bearing potential   
f   Nasal epithelial cell samples will be collected at sites  with the capability to perform the collection and  from s ubjects who have provided consent for DNA samples .  The 
procedure is not visit specific,  should only be performed once per subject at which ever visit (either during Part A OR Part B) is deemed most convenient.  For MCC Sub -
Study it is likely more convenien t to perform the collection at either Visi t 4B or 5B due to the number of procedures required at Visit 4 and 5 respectively .   
g  The spirometry procedure should be performed in concert with the sputum induction procedure to occur after short -acting bronch odilator  administration and prior to the 
sputum induction itself.  All spirometry testing should be performed between 15 ±5 minutes post-bronchodilator administration.  
h  Before conducting the sputum induction procedure, confirm that the subject meets the criteria to perform the procedure (no history of massive hemoptysis within 72 hours of 
the procedure, pre -albuterol spirometry FEV1 is >30% of predicted, and able to tolerate procedure).  If the induction procedure cannot be perfor med and if the subject ca n 
expectorate good quality sputum sample (defined as a minimum 0.5 mL sputum volume with visible mucus plugs), expectorated spu tum will be obtained.  *Note: For MCC 
Sub-study sputum induction is performed at Visit 4B and Visit 5B.)  
i  Subjects in the GIFT  and pH Pill sub-studies will be contacted prior to each visit to be reminded about GIFT  and pH Pill  sub-study  requirements.  
j  Fecal collection kits will be provided to subjects with instructions on how to collect and freeze at home and then return the  samples to the clinic at Visits 4 and 6 respectively. 
Subjects who participated in Part A and provided a fecal sample at Visit 2 do not need to collect a second baseline sample pr ior to Day 1.  
k  Breath Test times:  a baseline breath test will be obtained within 1 5 minutes before glucose ingestion. Subsequent tests will be obtained at 15, 30, 45, 60, 90 and 120 minutes 
(±5 minutes) after the completion of glucose ingestion.   
m  See Protocol Section 9 for suggested order of procedures to accommodate both th e CORE  and the sub -study procedures.  
n  Subjects will  drink 1.75 gm/kg  (maximum 75 grams) of glucose (GlucoCrush)  
o  OGTT blood draw times:  a baseline blood draw will be obtained within 1 5 minutes before glucose ingestion. Subsequent blood draws will b e obtained at 30, 60, 90, and 120 
minutes  (±5 minutes)  after the completion of glucose ingestion.  
p  Subjects should have  a snack within 15 minutes  after the last OGTT blood draw  (and breath test, as applicable)  to prevent reactive hypoglycemia.  
q  Subje cts should swallow the pH pill when ingesting the GlucoCrush.  
r   Subjects who participate in PART A pH Pill do not need to repeat the procedure at Visit 4 if Visit 2 (Part A) occurred within  9 months  (270 days)  of Day 1.  
s  FENO procedure will performed before MBW at selected sites.  
t   Subjects participating in MCC sub -study will be contacted prior to the visit in order to be reminded about MCC sub -study requirements (discontinue use of excluded 
medications).  
u   Before performing MCC measurement, confir m subject meets the criteria to perform the test ( Visit 5 pregnancy test is negative  (if applicable) , subject has held the required 
medications, and has not required antibiotics or corticosteroids for  acute  lower respiratory tract symptoms in the last 2 we eks) . 
v  Short acting bronchodilator is administered 60 ±10 minutes prior to isotope inhalation for MCC procedure. The timing of administration prior to MCC procedure should be 
consistent for each patient for each visit.  
w  At Visit 4  and 5 , a transmissi on scan is performed prior to the MCC procedure.  
Protocol PROSPECT                                                                                                                      Confidential  
 
Version #:  4.0 Version Date: 2016_0909   Page 104 of 104 
Protocol Template © CFFT TDN   Effective: 28 DEC 2012  x  Before performing the pH pill test, confirm subject meets the criteria to perform the test ( Visit 5 pregnancy test is negative  (if applicable) , subject has held the required 
medications , and has not had l oose watery stools within the last two weeks more than three times a day lasting more than 24 hours, or has not been vomiting  within the two 
weeks prior to the visit ) 
 
 